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Abstract 
The innate immune system provides an essential first line of defense against 
infection.  Innate immune cells detect pathogens through several classes of Pattern 
Recognition Receptors (PRR) allowing rapid response to a broad spectrum of infectious 
agents.  Activated receptors initiate signaling cascades that lead to the production of 
cytokines, chemokines and type I interferons all of which are vital for controlling 
pathogen load and coordinating the adaptive immune response.  Detection of nucleic 
acids by the innate immune system has emerged as a mechanism by which infection is 
recognized.  Recognition of DNA is complex, influenced by sequence, structure, covalent 
modification and subcellular localization.   
Interestingly certain synthetic oligodeoxynucleotides comprised of the TTAGGG 
motif inhibit proinflammatory responses in a variety of disease models.  T hese 
suppressive oligodeoxynucleotides (sup ODN) have been shown to directly block TLR9 
signaling as well as prevent STAT1 and STAT4 phosphorylation.  Recently AIM2 has 
been shown to engage ASC and assemble an inflammasome complex leading to the 
caspase-1-dependent maturation of IL-1β and IL-18.  T he AIM2 inflammasome is 
activated in response to cytosolic dsDNA and plays an important role in controlling 
replication of murine cytomegalovirus (MCMV).  In the second chapter of this thesis, a 
novel role for the sup ODN A151 in inhibiting cytosolic nucleic acid sensing pathways is 
described.  Treatment of dendritic cells and macrophages with the A151 abrogated type I 
IFN, TNF-α and ISG induction in response to cytosolic dsDNA.  A151 also reduced INF-
β and TNF-α induction in BMDC and BMDM responding to the herpesviruses HSV-1 
and MCMV but had no effect on the responses to LPS or Sendai virus.  In addition, A151 
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abrogated caspase-1-dependent IL-1β and IL-18 maturation in dendritic cells stimulated 
with dsDNA and MCMV.  A lthough inhibition of interferon-inducing pathways and 
inflammasome assembly was dependent on backbone composition, sequence 
differentially affected these pathways.  While A151 more potently suppressed the AIM2 
inflammasome, a r elated construct C151, proved to be a more potent inhibitor of 
interferon induction.  A151 suppressed inflammasome signaling by binding to AIM2 and 
competing with immune-stimulatory DNA.  The interaction of A151 and AIM2 
prevented recruitment of the adapter ASC and assembly of the macromolecular 
inflammasome complex.  C ollectively, these findings reveal a new route by which 
suppressive ODNs modulate the immune system and unveil novel applications for 
suppressive ODNs in the treatment of infectious and autoimmune diseases. 
The innate immune response to HSV-1 infection is critical for controlling early 
viral replication and coordinating the adaptive immune response.  The cytokines IL-1β 
and IL-18 are important effector molecules in the innate response to HSV-1 in vivo.  
However, the PRRs responsible for the production and maturation of these cytokines 
have not been fully defined.  In the third chapter of this thesis, The TLR2-MyD88 
pathway is shown to be essential for the induction of pro-IL-1β transcription in dendritic 
cells and macrophages responding to HSV-1.  The HSV-1 immediate-early protein ICP0 
has previously been shown to block TLR2 responses and in keeping with this finding, 
ICP0 blocked pro-IL-1β expression.  Following translation, pro-IL-1β exists as an 
inactive precursor that must be proteolytically cleaved by a multiprotein complex known 
as the inflammasome to yield its active form.  Inflammasomes are composed of 
cytoplasmic receptors such as NLRP3 or AIM2, the adapter molecule ASC, and pro-
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caspase-1.  In the present study we found that the NLRP3 inflammasome is important for 
maturation of IL-1β in macrophages and dendritic cells responding to HSV-1.  In contrast 
the related NLRP12 protein controls IL-1β production in neutrophils.  These data indicate 
that sensing of HSV-1 by TLR2 drives pro-IL-1β transcription and infection activates the 
inflammasome to mature this cytokine.  Moreover, these studies reveal cell type-specific 
roles for NLRP3 and NLRP12 in inflammasome assembly. 
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Chapter I 
 
1.1 Introduction 
 
The human immune system can be divided into two main components, the innate 
and the adaptive responses.  The innate immune response is the first line of defense 
against pathogens.  This response is coordinated by a variety of specialized cells 
including monocytes, macrophages, dendritic cells (DCs), neutrophils, eosinophils, 
basophils, natural killer (NK) cells, and NK T cells.  These cells are activated by 
germline-encoded Pattern Recognition Receptors (PRRs).  PRRs bind to molecular 
signatures, often-essential structural or genetic components, which are conserved among 
pathogens.  This allows the innate immune system to respond rapidly to a broad range of 
infectious agents that have breached the skin and mucous membranes.  In contrast, the 
adaptive immune system is slow to mobilize but provides a highly antigen specific 
response. This is accomplished through the somatic recombination of T and B cell 
receptors and provides a mechanism for long-lived specific immunity.   
The innate immune system is essential for controlling pathogen load and 
activating the adaptive immune response.  T he importance of innate immunity is 
highlighted by hereditary deficiencies in this response such as that seen in chronic 
granulomatous disease which leaves the host susceptible to recurrent bouts of infection 
(1).  On the other hand, aberrant or uncontrolled immune responses can cause extensive 
tissue damage, exacerbate septic shock and contribute to the development of autoimmune 
diseases (2).  T hus, a balance between activation and suppression must be struck to 
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ensure an appropriate and effective immune response.  U nderstanding how the innate 
immune system is activated and how this response may be controlled will help in 
designing safe and effective therapeutic interventions.   
 
1.2 Pattern Recognition Receptors 
 
Innate immune cells detect pathogens through distinct classes of germline-
encoded Pattern Recognition Receptors (PRR) including the Toll-like receptors (TLRs), 
the RIG-I-like receptors (RLRs), the NOD-like receptors (NLRs) and the AIM2-like 
receptors (ALRs; also known as the PYHIN family of receptors).  These PRRs respond to 
a variety of conserved pathogen- and danger-associated molecular patterns 
(PAMPs/DAMPs) allowing rapid recognition and response to infectious agents.  
Activated receptors initiate signaling cascades that lead to the production of cytokines, 
chemokines and type I interferons, all of which are vital for controlling pathogen load 
early on and coordinating an effective adaptive immune response.  Though the 
importance of these effectors was first recognized more than half a century ago, only in 
the past decade have we begun to understand the precise molecular pathways that lead to 
their production.  The Toll-like receptors were the first group of PRRs discovered.  TLRs 
mainly recognize PAMPs and DAMPs in the extracellular and endosomal compartments.  
More recently a number of PRRs, including the RLRs, NLRs and ALRs have been 
identified which survey the cytoplasmic and, in some cases, even the nuclear 
compartments.  In the following sections these PRRs will be reviewed in detail with 
particular emphasis given to the sensing of DNA within the cytosol. 
 3 
 
1.2.1 Toll-like receptors 
 
Of the PRRs, the Toll-like receptors (TLRs) are the most extensively studied.  
TLRs are type 1 transmembrane proteins that traffic between the plasma membrane and 
endosomal vesicles.  Those located on the plasma membrane are usually specific for 
hydrophobic lipids and proteins while those found in the endosome detect nucleic acids.  
This segregation allows innate cells to respond to components of the viral envelope and 
bacterial cell wall at their surface.  In contrast, nucleic acids are detected in the endosome 
where many viruses uncoat their genomes and enter the cytoplasm.  To date, 10 T LRs 
have been identified in humans while 13 have been identified in mice with TLRs 1-9 
common to both.  TLR1, TLR2, TLR4, TLR5 and TLR6 are located on the plasma 
membrane while TLR3, TLR7, TLR8, and TLR9 are endosomal.  TLR2 forms 
heterodimers with either TLR1 or TLR6 and can respond to a variety of lipoproteins, 
peptidoglycan and liptechoic acid (3, 4).  TLR4 is activated by LPS, a crucial component 
of the bacterial cell wall of gram-negative bacteria (5).  T LR5 responds to flagellin a 
component of the flagellum, a highly conserved structure among motile bacteria (6).  
TLR3 recognizes dsRNA while TLR7 and TLR8 recognize ssRNA, species that are often 
associated with viral infection and replication (7).  T LR9 is activated by unmethylated 
CpG DNA motifs that are common in bacterial and viral genomes but underrepresented 
in vertebrate DNA (8).   
All TLRs share a common architecture consisting of extracellular leucine-rich 
repeats and a cytoplasmic Toll/Interleukin-1 Receptor (TIR) domain (9).  These receptors 
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signal as dimers, differentially recruiting the adapter proteins: Myeloid differentiation 
primary response gene 88 (MyD88) and MyD88 adapter-like (Mal also known as TIRAP) 
and/or TIR-domain-containing adapter inducing IFN-β (TRIF) and TRIF-related adapter 
molecule (TRAM).  Adapters initiate signal cascades culminating in the activation of 
nuclear factor kappa b (NF-κB), mitogen-activated protein kinase (MAPK) and interferon 
regulatory factors 1, 3 , 5 and 7 ( IRF-1, 3, -5 and -7) (10). Together, these transcription 
factors not only drive expression of interferons, cytokines and chemokines, but also 
influence cellular proliferation, maturation and survival.  
The specific inflammatory response evoked by PAMPs and DAMPs depends on a 
variety of factors.  F irst, cellular expression of TLRs differs amongst innate cell types.  
Human macrophages are known to express high levels of TLR2 and TLR4 while 
plasmacytoid dendritic cells (PDCs) mainly express TLR7 and TLR9 (9).  E xpression 
patterns also vary between species.  W hile TLR9 is restricted to a f ew cell types in 
humans, it is widely distributed in mice (11).  F urthermore, expression of certain 
downstream signaling molecules fluctuates between innate cell types.  F or example, 
plasmacytoid dendritic cells (PDCs) are unique in that they constitutively express the 
transcription factor IRF7, allowing them to quickly produce high levels of type I IFNs in 
response to viral infection while other cell types such as macrophages may respond in a 
more delayed manner (10, 12).  T hus, the response to identical ligands may differ 
between cell types both in the nature of effector molecules produced and the kinetics of 
the response. 
 
1.2.2 Cytosolic sensors 
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All viruses and many bacteria enter the cell’s cytoplasmic compartment during 
their life cycles.  Viruses, such as HSV, gain entry via fusion of their envelope with the 
cell’s outer plasma membrane while other viruses, such as influenza, fuse in the 
endosomal vesicle.  During the process of viral replication the host’s own cellular 
machinery is co-opted to produce a large number of virions.  This process leads to the 
accumulation of viral nucleic acids, which are one of, if not the most common, cytosolic 
PAMP observed in viral infections (13).  The cytosolic PRRs responsible for detecting 
nucleic acids have been intensely investigated over the past few years and our body of 
knowledge has grown rapidly.  Cytosolic nucleic acid sensors can be divided into those 
that respond to RNA (RLRs) and those that respond to DNA (NLRs, ALRs, and others).  
Recent research has revealed that cytosolic DNA receptors lead to the activation of two 
distinct inflammatory pathways.  Activation of the first pathway results in the expression 
of type I interferons, cytokines and chemokines through the activation of IRF-3 and -7 
and NF-κB, respectively (13).  A growing number of receptors have been identified that 
activate this pathway though much debate still exists over the relative and specific 
contributions of each to effector induction.  The second pathway is characterized by the 
assembly of a ‘inflammasome complex’ and results in the caspase-1-dependent activation 
and secretion of IL-1β and IL-18.  Members of the NLR family of receptors were the first 
shown to activate this pathway (14, 15).  In addition, AIM2 a member of the PYHIN 
family, has also been shown to assemble an inflammasome (16, 17).  Our discussion will 
begin with the mechanisms of RNA sensing by RLRs and proceed to DNA sensing by 
NLRs, ALRs and other receptors. 
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1.2.3 Rig-I-like receptors 
 
The RLR family is comprised of three DExD/H box RNA helicases: retinoic acid-
inducible gene (RIG-I), melanoma differentiation-associated gene 5 (MDA-5) and 
laboratory of genetics and physiology-2 (LGP-2) (18-21).  Both RIG-I and MDA-5 are 
comprised of tandem N-terminal caspase activation and recruitment domains (CARDs) 
followed by a DExD/H box RNA helicase domain, which has ATPase activity, and a C-
terminal repressor domain (RD).   Unlike RIG-I and MDA-5, LGP-2 lacks the N-terminal 
CARD domains and contains only the RNA helicase domain.  As such, LGP-2 was 
postulated to act as a n egative regulator of the other RLRs (19, 21).  U nder resting 
conditions, RIG-I resides in the cytoplasm in an inactive form that is autoinhibited by its 
regulatory domain.  Upon binding dsRNA, RIG-I undergoes a conformational change and 
dimerizes in an ATP dependent manner (21).  The activated multimeric form of RIG-I or 
MDA5 interacts with the downstream adapter protein mitochondrial antiviral signaling 
protein (MAVS), also known as VISA, IPS-1, and CARDIF, via CARD-CARD 
interactions.  M AVS is found on t he outer leaflet of the mitochondrial membrane, a 
localization thought to be essential for downstream signaling (22).  Recently, MAVS has 
also been observed on peroxisomes, where it induces an early antiviral response through 
the direct induction of a subset of anti-viral genes via the transcription factor IRF1 (23).   
Upon engagement of RIG-I or MDA5, MAVS activates the IKK-related kinase (TBK1, 
also known as IKKi), which in turn, activates IRF-3 and IRF-7, resulting in the 
transcription of type I interferons (24). MAVS also activates NF-κB through recruitment 
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of TRADD, FADD, caspase-8, and caspase-10 resulting in cytokine and chemokine 
production (25-27). 
The RLRs are critical components of the anti-viral defense pathway in many cell 
types such as conventional dendritic cells as well as stromal cells (28). Initially, it was 
thought that both RIG-I and MDA-5 recognized the synthetic dsRNA, polyinosinic acid 
polyribocytidylic acid (polyI:C). However, studies using RIG-I- and MDA-5-deficient 
mice determined that MDA-5 alone was responsible for interferon production by polyI:C 
stimulation, while RIG-I recognized uncapped, 5’-triphosphorylated ssRNA, a common 
feature in many viral genomes (29).  Importantly, RIG-I is unable to recognize the host’s 
5’-capped ssRNA (30-32).  In addition, RIG-I is capable of recognizing short dsRNA, a 
byproduct of viral replication (33).  MDA-5 distinguishes between viral and host RNA, 
not by its 5’ end, but rather, by the length of the RNA sequence.  Long dsRNA is not 
naturally present in host cells but is produced during infection with certain viruses.  
RIG-I and MDA-5 recognize different classes of RNA viruses. Studies have 
implicated RIG-I in the recognition of vesicular stomatitis virus (VSV), rabies virus, 
Sendai virus (SV), Newcastle disease virus (NDV), respiratory syncytial virus (RSV), 
measles virus, Influenza A and B viruses, hepatitis C virus (HCV), Japanese encephalitis 
virus, and Ebola virus (28, 29, 34-36).  Studies using MDA-5-deficient mice show that it 
recognizes encephalomyocarditis virus (EMCV), Theiler’s murine encephalomyelitis 
virus (TMEV), coxsackie B virus (CVB) and polio (30, 35, 37, 38).  These viruses do not 
contain 5’-triphosphate RNA, but produce long dsRNA during replication, providing 
further evidence that MDA5 discriminates between self and non-self RNA based on 
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sequence length.  R ecent studies have shown some viruses, such as dengue, West Nile 
virus, and reovirus, signal through a combination of both RIG-I and MDA-5 (37, 39, 40).  
As mentioned above, LGP-2 lacks N-terminal CARD domains, and was first 
thought to be a negative regulator of RLR function (19, 21).  Initial studies found that 
overexpression of LGP-2 decreased the capacity of SV and NDV to induce interferon 
production.  E vidence that LGP-2 could associate with RIG-I through mutual RD 
domains led to the theory that LGP-2 directly prevented RIG-I association and activation.  
In addition, interferon signaling was found to be increased in LGP-2-deficient mice in 
response to polyI:C, providing evidence for negative regulation of MDA-5 as well (41).  
In contrast, a second in vivo study using LGP-2 deficient mice and mice harboring a 
inactivated version of LGP-2 showed that this protein acted as a p ositive regulator of 
RIG-I- and MDA-5-mediated signaling after infection.  Thus LGP-2 may, in fact, 
enhance RIG-I- and MDA-5-dependent viral recognition by promoting RNA 
accessibility.  
Another member of the DExD/H box RNA helicase family, DDX3 has been 
implicated in anti-viral defenses. Schroder et al. found that the vaccinia virus protein K7 
inhibited IFN-β induction by binding to DDX3, which led to the discovery that DDX3 
had a positive role in the RLR signaling pathway (42). A recent study reported that 
DDX3 binds to both polyI:C and viral RNA introduced into the cytosol and associates 
with MAVS and TBK-1 to upregulate IFN-β production. These results led the authors to 
speculate that DDX3 may enhance RNA recognition, forming a complex with RIG-I and 
MAVS to induce interferon production (43). Further studies are required to determine 
whether DDX3 is a bona fide RNA sensor or a component of the RLR signaling pathway.   
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1.2.4 Interferon-inducing cytosolic DNA receptors 
 
The detection of cytosolic DNA has emerged as an important mechanism by 
which pathogens are recognized and protective immunity is generated.  However, as 
recently as ten years ago, TLR9 was the only known sensor of foreign DNA.  Early 
studies by Dr. Shizuo Akira and colleagues hinted at the existence of additional sensing 
mechanisms.  One such study demonstrated that TLR9-deficient MEFs, which failed to 
respond to CpG DNA, produced large amounts of IFN in response to transfection with 
synthetic and viral dsDNA (44).  The Medzhitov lab reported similar findings using a 45 
bp interferon stimulatory DNA (ISD) derived from the Listeria monocytogenes genome 
(45).  Recently, a number of cytosolic sensors have been identified and purported to be 
essential for the interferon response to dsDNA.  These include DNA-dependent activator 
of IFN-regulatory factors (DAI), RIG-I via RNA polymerase III, Leucine-rich repeat 
flightless-interacting protein 1 (LRRFIP1), DEAD/H box peptides: DHX9, DHX36 and 
DDX41, cyclic GMP-AMP Synthase (cGAS) and interferon gamma-inducible protein 16 
(IFI16) (16, 17, 46-49).   
Like the cytosolic RNA recognition pathways, cytosolic DNA recognition leads 
ultimately to activation of TBK1 and IRF-3 and the production of type I IFN.  However, 
the signaling pathway(s) linking DNA sensors to TBK1 are poorly characterized.  TBK1 
associates with DDX3, discussed previously, which regulates IFN-β transcription via 
IRF-3 (42, 43).  In addition, TBK1 interacts with the exocyst protein Sec5 in a complex 
that includes the recently identified endoplasmic reticulum (ER) adapter stimulator of 
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interferon genes (STING) (27, 50-52).  In both humans and mice, STING is critical in the 
signaling pathway upstream of TBK1 following HSV-1 infection (27).  STING also 
interacts with the ER translocon components Sec61β and TrapB in a manner essential for 
regulation of cytosolic DNA-induced type I IFN production, although a mechanistic 
understanding of this relationship is not yet known (50).  In unstimulated cells, STING 
localizes to the ER and mitochondria (52, 53).  Following stimulation with cytosolic 
DNA and HSV-1, STING translocates to perinuclear foci, via the Golgi.  One report 
suggests STING localizes partially to endosomes, particularly Sec5 positive structures 
(27), while another report argues that STING localizes to vesicular structures, which are 
not peroxisomes, mitochondria, endosomes or autophagosomes (54).  In contrast, more 
recent evidence suggests STING can signal from the mitochondrial membrane in 
response to certain stimuli (53).  Moreover, an intact mitochondrial membrane potential 
is essential for an optimal response.  Further work is required to determine the precise 
subcellular localization of STING.  What is evident is the essential role of STING in 
cytosolic DNA sensing pathways.  Much less clear is the mechanisms or receptors which 
act upstream of STING.  A growing number of receptors that utilize the STING-TBK1-
IRF-3 pathway have been implicated in cytosolic DNA sensing and will be outlined 
below.  
 
DAI.  DNA-dependent activator of IFN-regulatory factors (DAI) was the first cytosolic 
DNA sensor discovered.  It is composed of two binding domains for left-handed, Z form 
DNA, although the protein can recognize B form DNA a s well (55).  When DAI was 
exogenously expressed in L929 cells, it increased type I IFN production in a dose 
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dependent manner following stimulation by both B and Z form DNA.  Similarly, 
knockdown of DAI impaired type I IFN production in response to the 45 bp ISD motif 
and HSV-1 (55).  The production of type I interferons by fibroblasts in response to 
HCMV was also found to be dependent on DAI (56).  Surprisingly, studies using DAI-
deficient mice found normal immune responses to synthetic and viral dsDNA (57).  
Moreover DAI-deficient mice had normal responses to a DNA vaccine suggesting that 
DAI may play a cell-type specific or redundant role in sensing cytoplasmic DNA (58). 
 
RNA polymerase III.  Two groups have shown that AT-rich DNA can be transcribed by 
RNA polymerase III into 5'-ppp RNA, which subsequently activates RIG-I (47, 48).  This 
pathway was reported to be involved in type I IFN induction during EBV infections.  The 
RNA Pol III-RIG-I pathway was also reported to be involved in induction of type I IFN 
following HSV-1 or Legionella pneumophila infection (47, 48, 59) .  However, other 
groups have cast doubt on these claims suggesting that RIG-I only detects L. pneumophia 
RNA and not DNA (60).  Moreover the MAVS signal molecule is not required for 
cytosolic DNA signaling in macrophages (61).  Thus, the RNA Pol III-RIG-I pathway 
may play a cell-type specific role, but appears to be redundant in macrophages.  
 
LRRFIP1.  In addition to DAI and RNA Pol III, Leucine-rich repeat flightless-
interacting protein 1 (LRRFIP1) has recently been implicated as a regulator of DNA-
driven innate immune signaling. LRRFIP1 was originally identified due to its role in 
actin organization during drosophila embrogenesis. In a study using Listeria 
monocytogenes to screen for potential cytosolic DNA sensing molecules, knockdown of 
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LRRFIP1 was found to inhibit the type I IFN response (62).  The authors showed that the 
IFN response to VSV was dampened in these cells as well.  Knockdown of LRRFIP1 also 
inhibited IFN production in response to polyI:C, and the synthetic DNA species, 
poly(dG:dC) and poly(dA:dT), implicating LRRFIP1 in the recognition of dsRNA and 
dsDNA.  Surprisingly, this function was independent of RNA Pol III.  In stark contrast to 
other DNA sensors, LRRFIP1 did not activate IRF3, but rather, regulated a novel β-
catenin-dependent coactivator pathway (63). LRRFIP1 bound RNA or DNA and led to 
the phosphorylation of β-catenin, which subsequently translocated to the nucleus where it 
associated with the p300 acetyltransferase at the IFN-β1 promoter, thereby inducing 
transcription.  Further studies are needed in order to determine LRRFIP1’s role in vivo.  
 
DHX9 and DHX36.  DEAH (Asp-Glu-Ala-His) box polypeptides 9 and 36 (DHX9 and 
DHX36), members of the DEAD/H box helicase family, have recently been shown to 
bind CpG-B and CpG-A DNA, respectively, in PDCs.  Activation of DHX9 leads to IRF-
7 activation and IFN-α production, while activation of DHX36 leads to NF-κB activation 
and IL-6 and TNF-α production (64).  Knockdown of DHX9 and DHX36 inhibited 
cytokine production in response to the DNA virus HSV-1, while the response to the RNA 
virus influenza A was unaffected.  
 
DDX41.  DEAD (Asp-Glu-Ala-Asp) box polypeptide 41 (DDX41), another member of 
the DEAD/H helicases family, was recently identified as a sensor of cyclic diguanosine 
monophosphate (c-di-GMP) and cyclic diadenosine monophosphate (c-di-AMP), two 
secondary messengers used by certain species of bacteria to regulate metabolism, motility 
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and virulence (65, 66).  Knockdown of DDX41 in mouse and human cells reduced IFN-β 
and IL-6 production in response to c-di-AMP, c-di-GMP, poly(dA:dT) and HSV-1 
infection (49, 67).  Bi nding of DNA to DDX41 was mediated by the DEADc domain. 
DDX41 was then found to associate with STING and TBK1 leading to downstream type I 
IFN and cytokine induction. 
 
cGAS.  Cyclic GMP-AMP Synthase (cGAS) is a member of the nucleotidyltransferase 
family that has recently been described as a c ytosolic sensor of DNA (68).  
Overexpression of cGAS in HEK293T cells led to IRF3 dimerization and IFN-β 
induction in a STING-dependent manner.  In contrast, knockdown of cGAS in L929 cells 
inhibited IFN-β induction in response to transfected DNA and HSV-1 infection.  cGAS, 
activated by dsDNA, catalyzed the synthesis of cGAMP from ATP and GTP which then 
bound to and activated STING leading to IFN-β expression (69).   
 
IFI16.  While analyzing immune responses to a dsDNA region derived from the VACV 
and HSV-1 genomes, Unterholzner et al. identified IFI16, a PYHIN protein family 
member, as a DNA binding receptor that interacted with these dsDNAs (Fig. 1.1) (70).  
Knockdown of IFI16 or p204 (a member of the murine PYHIN family) led to a reduction 
in IFN-β responses to these dsDNAs while responses to the RNA virus SV was 
unaffected.  A lthough IFI16 is primarily nuclear in most cell types, in macrophages, 
IFI16 is also found in cytosol where it co-localizes with transfected dsDNA. Association 
of IFI16 with STING was required for the production of IFN-β in response to these DNA 
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motifs.  Knockdown of IFI16, and its mouse ortholog p204 led to a decrease in IRF3 and 
NF-κB activation and IFN-β gene induction following HSV-1 infection (70).  IFI16 and 
other members of the PYHIN family are discussed in greater detail below.   
 
1.2.5 PYHIN receptors 
 
 The founding member of the PYHIN (pyrin and HIN200 domain-containing) 
family, p202a was first identified over two decades ago.  Since then four PYHIN proteins 
have been reported in humans (IFIX, IFI16, MNDA and AIM2) and six in mice (p202a, 
p202b, p203, p204, MNDAL and AIM2) though seven additional murine members are 
predicted.  PYHIN receptors are differentially expressed in hematopoietic cells and can 
be upregulated by type I a nd II IFN signaling (71).  All contain one or more HIN200 
domains and, with the exception of p202a and b, all have N-terminal pyrin domains.  
These HIN200 domains were later categorized into subtypes, A, B and C, according to 
their sequence similarity.  IFI16, and its murine ortholog p204, have both HIN200A and 
B domains, while AIM2 contains a single HIN200C domain (Fig. 1.2).  E ach HIN200 
domain is comprised of two oligonucleotide/oligosaccharide binding (OB) folds that 
associate with DNA.  These OB folds were first predicted based on modeling of IFI16’s 
HIN200A domain using the human replication protein A (RPA) as a template (72).  This 
study went on to show that IFI16’s HIN200A domain had a higher affinity for ssDNA 
than dsDNA and could wrap and stretch ssDNA.  The crystal structures of the IFI16 and 
AIM2 HIN200 domains revealed that DNA binding was accomplished through 
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electrostatic interactions between the positively charged HIN200 residues and the 
negatively charged dsDNA sugar-phosphate backbone.  This observation explains why 
activation of IFI16 and AIM2 appears to be largely sequence-independent (73).  This 
study suggested unbound AIM2 is maintained in an autoinhibited state by the 
intramolecular association of its HIN200C and pyrin domain, which is liberated by 
binding to dsDNA.  IFI16, MNDA and p204 contain nuclear localization signals and are 
mainly found within the nucleus though IFI16 can be observed within the cytoplasm (17, 
70).  AIM2 and p202 by comparison are localized to the cytoplasm. 
The IFI16 mRNA is spliced into three transcripts that differ according to the 
length of the serine-threonine-proline-rich spacer sequence that separates the HIN200A 
and B domains (74).  Initial biochemical analysis of IFI16 fused to the GAL4DBD 
revealed it could act as a potent transcriptional repressor though the molecular 
mechanisms underlying this function are unknown (75).  Early in vitro experiments found 
IFI16 associated with p53 and pRb and, when overexpressed, could slow cell growth by 
delaying G1 to S phase progression (75).  Transcriptional silencing of IFI16 has been 
implicated in the development of prostate and breast cancer (76, 77).  IFI16 has also been 
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shown to associate with BRCA1.  This interaction was found to enhance genotoxic stress-
induced cell death through p53-mediated apoptosis, suggesting a role for IFI16 in 
mediating DNA damage signaling (76, 78).  In addition IFI16 has been suggested to 
induce apoptosis in endothelial cells by activating NF-κB leading to caspase-2-mediated 
apoptosis independent of p53 (79).  The proapoptotic activity of IFI16 has lead to the 
theory that it may play an etiopathogenetic role in autoimmunity.  Indeed, PBMCs 
isolated from lupus patients have elevated IFI16 mRNA levels and anti-IFI16 antibodies 
are common in Systemic Lupus Erythematosus (SLE), Systemic Slerosis and Sjogren’s 
Syndrome (80, 81).  Thus, a number of genetic and functional studies have linked IFI16 
to autoimmunity and cancer.  However, the specific pathways through which IFI16 
mediates its affects on cellular proliferation and survival are still debated.  
Recently, dsDNA sequences derived from the HSV-1 and VACV genomes were 
shown to bind IFI16, which activated the STING-TBK1-IRF-3 pathway leading to the 
production of type I IFNs.  Knockdown of either IFI16 or its murine ortholog p204 also 
led to a decrease in IRF3 and NF-κB activation following in vitro infection with HSV-1.    
Intriguingly, a recent study has revealed a role for IFI16 in inflammasome assembly in 
response to Kaposi sarcoma-associated herpesvirus (KSHV).  In endothelial cells, IFI16 
in the nucleus can interact with KSHV DNA and the inflammasome adapter molecule 
ASC leading to the activation of caspase-1 and IL-1β secretion (82).  This case of IFI16-
mediated inflammasome signaling may be the exception rather than the rule, as AIM2 
appears to be the main inflammasome-assembling receptor that responds to cytosolic 
dsDNA.  AIM2 was first identified as a putative tumor suppressor in the human 
malignant melanoma cell line UACC903 (83).  Mutations in the aim2 gene have been 
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associated with colorectal tumors, gastric and endometrial cancers suggesting like IFI16, 
AIM2 plays a role in cell cycle progression (84, 85). In support of such a function, 
restoration of AIM2 expression in colorectal cancer cell lines leads to cell cycle arrest 
(86).  Recently, AIM2 was shown to assemble an inflammasome in response to a variety 
pathogens, including MCMV, VACV, Francisella tularensis and Listeria 
monocytogenes.  A IM2 and its role in inflammasome signaling is discussed further 
below.    
 
1.2.6 NOD-like receptors and the Inflammasome 
   
In contrast to type I IFNs and TNF-α, the production of IL-1β and IL-18 is 
controlled at the level of transcription, translation, maturation and secretion.  IL-1β is a 
pleiotrophic cytokine that induces fever, activates monocytes, macrophages and 
neutrophils and drives acute-phase protein synthesis (87).  IL-18 increases natural killer 
(NK) cytolytic activity and IFN-γ production thereby inducing Th1 and Th17 adaptive 
responses (88, 89).  Many cell stimuli including TLR ligands activate the NF-κB-
dependent transcription of the pro-forms of IL-1β and IL-18.  U nlike most other 
cytokines, however, these pro-cytokines lack leader sequences and are retained in the 
cytoplasm rather than loaded into secretory vesicles.  Maturation (i.e., the cleavage) of 
pro-IL-1β and pro-IL-18 is catalyzed by the cysteine protease caspase-1 (formerly known 
as IL-1 converting enzyme).  In resting cells, caspase-1 itself is present as an inactive 
zymogen pro-caspase-1.  A large inflammasome protein complex controls the activity of 
the inflammatory caspase-1.  Several members of the nucleotide-binding oligomerization 
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domain receptor (NLR) family, including NLRP1, NLRP3, NLCR4 (IPAF) and NLRP12 
have been shown to assemble inflammasomes in response to various stimuli.   
The NLR family includes 23 genes in humans and 34 i n mice (90).  T hey are 
composed of a C-terminal LRR-rich domain, a central nucleotide-binding NACHT 
oligomerization domain, and an N-terminal protein–protein interaction pyrin domain 
(PYD) or in the case of NLRC4 an N-terminal caspase activation and recruitment domain 
(CARD).  NLRs associate with the PYD containing adapter molecule apoptosis-
associated speck-like protein (ASC; also termed pycard or TMS1).  ASC links the NLRs 
via its C-terminal CARD domain to the CARD domain of pro-caspase-1.  This close 
association of pro-caspase-1 molecules is then believed to enable self-cleavage into 
active caspase-1.  Active caspase-1 in turn cleaves pro-IL-1β and pro-IL18 into their 
active forms.  
In addition to pro-IL-1β and pro-IL-18, expression of certain NLRs, such as 
NLRP3, is upregulated in an NF-κB-dependent manner (91).  The NLRP3 inflammasome 
is activated by a wide range of PAMPs and DAMPs such as ATP, the pore forming toxin 
nigericin, uric acid, silica, cholesterol and asbestos crystals, the vaccine adjuvant alum, 
chemotherapeutics including gemicitabine and 5-fluorouracil, as well as by fibrillar 
amyloid-β (92-97).  A number of pathogens have been shown to activate NLRP3 
including influenza A virus, adenovirus, Sendai virus, Staphylococcus aureus, Listeria 
monocytogenes and Candida albicans (15, 95, 9 8-100).  In the case of Gram-negative 
bacteria like enterohermorrhagic Escherichia coli and Citrobacter rodentium, caspase-11 
induction via the TLR4-TRIF-IFN-β pathways is also essential for NLRP3 activation 
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(101).  Despite the identification of these triggers, no ligand has been shown to directly 
bind to NLRP3 and the mechanism by which NLRP3 is activated remains unclear.   
Three models of NLRP3 activation have been proposed.  However, no single 
model can yet account for all activating stimuli.  The first posits that disruption of cell 
membrane ionic gradients may activate NLRP3.  T his model is supported by evidence 
that extracellular ATP activates the P2X2 receptor causing potassium efflux that results in 
NLRP3 activation (102, 103).  This may explain how bacterial pore-forming toxins such 
as nigericin activate NLRP3.  In addition, studies using influenza A virus revealed that 
the M2 protein, a proton-specific ion channel, was necessary to trigger NLRP3 activation 
(104).  However certain bacteria are able to activate NLRP3 independently of the P2X2 
receptor suggesting that alternative pathways exist (102).  A second model suggests that 
destabilization or rupture of the lysosomal membrane by crystals, chemotherapeutics or 
bacteria leads to the release of enzymes such as cathepsin B or L that activate NLRP3 
(96, 97).  In support of this theory, pharmalogical inhibition of cathepsin B reduced 
NLRP3 activation by cholesterol crystals (97).  However, another study indicated that 
NLRP3 activation was independent of cathepsin B or L at higher doses of cholesterol and 
had no effect on stimulation with other NLRP3 triggers (105).  The third model proposes 
that reactive oxygen species (ROS) generated by DAMPs, such as silica and cholesterol 
crystals can activate NLRP3 (106, 107).  I ndeed, studies have shown the addition of 
hydrogen peroxide can cause NLRP3 inflammasome activation and inhibition of ROS 
can suppress this activation.  However ROS are created in response to a variety of stimuli 
and not all pathways that induce ROS activate the inflammasome (108).  Finally, a study 
using Mycobacterium kansasii reported a role for all three pathways (109).  Further 
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research on the precise molecular events underlying NLRP3 activation are needed to 
determine if these pathways are, in fact, causal or simply parallel responses and whether 
they are specific to certain stimuli or act cooperatively.     
Unlike NLRP3, NLRC4 can recruit caspase-1 directly through its CARD domain 
and does not necessarily require ASC (110).  However, NLRC4 also signals through an 
ASC-dependent pathway and ASC is required for maximal activity in certain cases.  
NLRC4 is activated by the flagellin peptide, in a manner that depends on NAIP5, and by 
the inner rod component of the bacterial type III secretion system (111).  P athogens 
including Pseudomonas aeruginosa, Salmonella typhimurium, Shigella flexeri, 
Legionella pneumophila have been demonstrated to activate NLRC4 (112-115).  NLRP1, 
the first NLR shown to assemble an inflammasome, is activated by anthrax lethal toxin 
derived from Bacillus anthracis (116).   
Recently, NLRP12, also known as Monarch-1 and PYPAF7, was shown to 
assemble an inflammasome in response to Yersinia pestis (117).  In this study, NLRP12-
deficient mice had reduced levels of IL-1β and IL-18 in their serum and were more 
susceptible to Y. Pestis infection.  NLRP12 expression has been observed in both human 
and mouse granulocytes and at lower levels in monocytes and DCs, but is undetectable in 
resting macrophages and lymphocytes (118).  Previous studies have found both pro- and 
anti-inflammatory roles for NLRP12.  One study showed that NLRP12 activated NF-κB 
and mediated caspase-1-dependent cytokine secretion (118) while another group reported 
that NLRP12 suppressed noncanonical NF-κB activation by destabilizing NF-κB 
inducing kinase (NIK) (119-121).  Interestingly, in a model of contact hypersensitivity, 
NLRP12-deficient mice were found to have impaired dendritic cell and neutrophil 
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migration, but no de fect in TNF-α or IL-1β production was observed (122).  Another 
study reported NLRP12 deficiency increased susceptibility to DSS-induced experimental 
colitis and colitis-associated colon cancer (123).  This was attributed to enhanced 
noncanonical NF-κB and MAPK activation in NLRP12-deficient mice.  It is possible that 
NLRP12 affects multiple inflammatory pathways that are tissue or cell-specific, thus, its 
activity may manifest itself differently depending on the disease or pathology examined.  
It is important to note that NLRP12 is highly similar to NLRP3, sharing 58% of its 
nucleotide sequence (124).  In humans, mutations in NLRP12, much like mutations in 
NLRP3, have been shown to cause hereditary periodic fever syndrome (HPFS) 
characterized by high fever, arthralgia, myalgia and sensorineural hearing loss (124).  
These NLRP12-associated HPSFs can be successfully treated with anti-IL-1 therapy, 
suggesting NLRP12 has a similar role to NLRP3 in vivo (124).   
Cytosolic dsDNA triggers ASC-dependent activation of caspase-1 and secretion 
of IL-1β and IL-18.  However, analysis of this response in macrophages lacking members 
of the NLR family revealed normal caspase-1 activation.  S ubsequent studies from 
several groups revealed that this response was instead dependent on the Absent in 
melanoma-2 (AIM2) protein (16, 17, 100, 125, 126). AIM2 recognizes cytosolic dsDNA 
of self and nonself origin via its HIN200C domain.  Upon DNA binding, AIM2 
oligomerizes and associates with ASC via its PYD domain.  ASC then recruits pro-
caspase-1 leading to its activation (Fig. 1.3).  AIM2 is essential for inflammasome 
formation and IL-1β and IL-18 secretion in macrophages and dendritic cells responding 
to infection with MCMV and VACV (16).  AIM2-dependent IL-18 secretion induces 
NK-cell activation and IFN-γ production that is critical for controlling MCMV 
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replication.  AIM2 has also been shown to recognize bacterial pathogens including 
Francisella tularensis and appears to be critical in early control of F. tularensis infection 
in vivo (16).  A IM2 also synergizes with NLRP3 and IPAF to drive IL-1β and IL-18 
secretion in response to Listeria monocytogenes (46). 
 
1.3  Suppressive Oligodeoxynucleotides 
 
Since the inhibitory effects of certain DNA sequences on TLR9 signaling were 
first reported, a variety of different DNA constructs or suppressive oligodeoxynucleotides 
(sup ODNs) that vary in length, sequence and backbone composition have been examined 
in vitro and in vivo.  Studies using dissimilar systems have drawn different, seemingly 
conflicting conclusions.  This confusion is compounded by the fact that certain sup ODNs 
block multiple pathways and cause cell type-specific effects.  In order to facilitate 
characterization, Trieu et al. divided sup ODNs into four groups based on their proposed 
mechanisms of action (127).  Class I consists of short G-rich sup ODNs that inhibit TLR9 
signaling in a sequence-specific manner.  C lass II interfere with STAT1, 3 a nd 4 
signaling.  Class III prevent cellular uptake by competing for surface receptors, and Class 
IV consists of long phosphorothioate constructs that inhibit TLR9 in a largely sequence-
independent manner.  Though this classification system mainly addresses the effects of 
sup ODNs on TLR9 signaling, it provides a useful framework for interpreting how sup 
ODNs interfere with other signal pathways.  As we will see some sup ODNs display 
characteristics of multiple classes.  
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1.3.1  The phosphorothioate backbone 
 
Phosphorothioate (PS) backbones are widely used in stimulatory ODN constructs 
to activate TLR9, as well as in antisense constructs to mediate transient protein 
knockdown.  These constructs differ from phosphodiester (PD) backbones in that one of 
the nonbridging oxygens is replaced with a s ulfur molecule.  This change not only 
imparts resistance to nuclease degradation, but it also increases cellular uptake (128-131).  
In addition PS-modified ODNs are known to bind a variety of proteins that do not  
interact with PD ODNs such as fibroblast growth factor (FGF) and vascular endothelial 
growth factor (VEGF) and have been shown to affect cell growth, morphology and viral 
proliferation independently of sequence (132-138).  Unfortunately, how PS constructs 
mediate their sequence-independent effects is not well understood.    
 
1.3.2  Modulation of innate immunity by Suppressive ODNs 
 
Halpern et al. first reported the inhibitory effects of G-rich phosphorothioate 
DNA on IFN-γ production nearly two decades ago (139).  This initial study found dose-
dependent inhibition of the IFN-γ response in splenocytes challenged with DNA derived 
from E. coli, Con A or PMA with the calcium ionophore A23187.  Inhibition required a 
PS backbone and though the poly(dG) sequence was optimal, the poly(dC) and poly(dT) 
constructs could also block activation.  Potency correlated positively with ODN length, at 
50 µg/ml, a 20 nucleotide poly(dG) sup ODN could achieve 92% inhibition of the IFN-γ 
response while a 10 n ucleotide construct achieved 51% inhibition.  Further studies 
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revealed that these sup ODNs could also block IL-6 and nitric oxide (NO) production by 
BMDM responding to CpG as well as IL-12 and NO production and CD40, CD86 and 
MHC II expression by BMDC (140, 141).  Again, PS constructs composed of any single 
base could inhibit CpG activation.  These effects were largely sequence-independent, but 
relied on long PS backbones (class IV).  It is possible that these sup ODNs also exerted 
class III effects as they did interfere with CpG uptake.  However, the dose required to 
inhibit uptake was higher than that required for suppression, arguing against a major 
contribution from this mechanism (141).  
In 1998, Kreig et al. reported that DNA derived from serotype 12 a denovirus 
stimulated TNF-α and IL-6 secretion from human PBMCs while DNA from serotypes 2 
and 5 were far less active (142).  They found that unlike serotype 12, types 2 and 5 had 
large numbers of clustered or directly repeating CG sequences within their genome.  
Treatment of splenocytes with PS hexameric constructs derived from these regions 
inhibited CpG ODN and E. coli DNA-induced cytokine secretion.  A  follow-up study 
revealed that these sup ODNs could also block CpG stimulation of mouse B cells and the 
authors suggested it did so by interfering with CpG binding to TLR9 (143).  This exciting 
report indicates that selective pressure to evade innate immune activation may have led to 
the enrichment of certain inhibitory motifs in viral genomes.  It is tempting to speculate 
about the role of such adaptations considering that adenovirus serotypes 2 and 5 (which 
contain the anti-inflammatory sequences) can establish latent infection in lymphocytes 
while serotype 12 cannot (144).  Unfortunately, it is hard to infer sequence specificity 
from these studies as the hexameric constructs used differed only in a few base positions 
and all had similar suppressive effects.  M oreover, other work using these sup ODN 
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motifs has shown only a modest role for sequence, again suggesting contributions from a 
class IV mechanism of action (145-147).   
The sup ODN 2114, a 15 bp construct, is one of the most potent, sequence-
specific inhibitors of TLR9 activation (class I) (146, 148).  This construct has been shown 
to block IL-6 and IL-12 production by mouse splenocytes in response to CpG.  I t also 
prevents IL-6 and IL-10 production and proliferation of human B cells and IFN-α and IL-
12 secretion by human PDCs (146).  Ashman et al. performed a series of experiments, in 
which each base in the 2114 construct was mutated, to define the sequence requirements 
for optimal inhibition (148).  This study found the optimal inhibitory motif consisted of a 
CC dinucleotide at the 3’ end, a spacer sequence of five nucleotides followed by at least 
three contiguous G residues (148).  Substitutions in this guanine tract rendered the 2114 
sup ODN inactive.  Some reports indicate a PS backbone is essential for 2114 
suppression while others maintain that the PD backbone version can still mediate 
suppression, but at a significantly reduced potency (127, 146).  Whether this difference is 
the result of increased uptake and retention of the PS version of 2114 leading to a higher 
intracellular concentration or is due to sequence independent contributions from the PS 
backbone (class IV) is unclear.  However, evidence that simply lengthening the backbone 
of the 2114 motif by as few as four or five base pairs can increase its inhibitory potency 
300-600% may indicate a transition from sequence-specific (class I) to a n onspecific 
(class IV) mechanism. 
Building on p revious evidence that mammalian DNA could suppress CpG-
induced immune activation, Gursel et al. reported that DNA derived from telomeres was 
particularly potent compared to whole genome extracts (149).  T his report found that 
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telomeres contained numerous copies of the guanine-rich, hexameric sequence 
TTAGGG.  Although a single repeat was weakly inhibitory, including multiple tandem 
repeats of the TTAGGG sequence produced a construct (TTAGGG)4, also known as 
A151, that potently inhibited IL-6, IL-12 and IFN-γ secretion from spleen cells in 
response to CpG ODN (149).  Much like 2114 the presence of guanine residues was 
thought essential for inhibitory activity.  This was the first example of a specific 
mammalian genomic motif that could suppress immune activation.  Its discovery has lead 
to the hypothesis that this motif, released from dead or dying host cells, may serve to 
suppress pathological immune responses.  Indeed, since this report, the therapeutic 
potential of A151 has been demonstrated in murine models of CpG and collagen-induced 
arthritis, toxic shock, systemic lupus erythematosus, atherosclerosis, silica-induced 
pulmonary inflammation and influenza infection (149-156).  D espite the broad 
applications of A151, there is still debate concerning the precise molecular mechanisms 
underlying its in vivo effects. 
Although the initial study by Gursel et al. claimed A151 synthesized with either 
PS or PD backbones could inhibit CpG-induced cytokine production at equimolar 
concentrations, they showed no da ta.  S ubsequent reports have only found inhibitory 
activity in A151 synthesized with a PS backbone (127, 146).  Moreover, this difference 
cannot be accounted for by variation in cellular uptake.  In addition, no role for sequence 
was reported in a later study, as A151-mediated inhibition was comparable to a poly(dA) 
PS construct of similar length (127).  Initial reports that A151 prevented activation by 
binding to CpG ODNs through the formation of four-stranded helices (G-tetrads) 
stabilized by planar Hoogsteen base pairing between guanine residues has not borne out 
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either (157).  As Duramad et al. demonstrated, despite containing three contiguous 
guanines, A151 does not readily form G-tetrads (146).  Moreover, when other constructs, 
such as 2114, that do form G-tetrads, are tested, it is the single-stranded species that 
mediates inhibition (146).  Thus, one early hypothesis that A151 mediated inhibition by 
binding and sequestering CpG appears to be incorrect.  Instead, A151 likely competes 
with CpG ODN for binding to TLR9 in a manner that depends on its PS backbone more 
so than sequence.  
Importantly, a number of observations suggest that inhibition of TLR9 signaling 
is not the only mechanism or even the main mechanism by which A151 and other sup 
ODN block immune activation in vivo.  For example, Shirota et al. demonstrated that 
A151 prevented Th1 differentiation in wild-type and TLR9-deficient CD4+ cells alike 
(154).  A recent study by Trieu et al. found treatment with 2114 suppressed NF-κB-
dependent responses to Salmonella typhimurium in both wild-type and TLR9-deficient 
macrophages (158).  Moreover, using a panel of sup ODNs, Ashman et al. reported 
optimal sequences for TLR9 inhibition as measured by biological assays did not correlate 
with their relative affinity for the TLR9 ectodomain (148).  Dennis Klinman and 
collaborators have reported one possible alternative A151-mediated mechanism of 
suppression.  Their studies show that A151 inhibits IFN-γ-induced STAT1 
phosphorylation and IL-12-induced STAT3 and STAT4 phosphorylation (class II 
mechanism) thereby preventing differentiation of naïve CD4+ cells into Th1 effectors 
(151, 153, 154) .  A ddition of A151 to splenocytes derived from OVA TCR Tg mice 
significantly inhibited IFN-γ production and Th1 differentiation while enhancing IL-4 in 
response to Ag-pulsed APCs (154).  This effect persisted despite the addition of IL-12 to 
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culture supernatants, suggesting a role in signal transduction downstream of the IL-12 
receptor.  A similar effect on IFN-γ signaling was observed in vivo when mice were 
immunized with OVA in the presence or absence of A151.  The magnitude of inhibition 
was dose-dependent and was not observed in mice treated with the C151 control ODN in 
which A151’s guanine triplet had been replaced with adenine residues.  A151 specifically 
blocked phosphorylation of STAT1, 3 and 4 but had no effect on STAT5 or 6.  Treatment 
with A151 also increased survival in a mouse model of LPS-induced endotoxic shock 
(153).  Though A151 had no effect on TNF-α, IL-12 or IFN-β induced directly by LPS, it 
abrogated subsequent paracrine and autocrine cytokine-induced IFN-γ production.  
Biotinylated A151 was used to pull down STAT1 and STAT4 from spleens cells 
stimulated with IFN-β (153).  The authors theorized that A151 interacts with the Src 
homology domain of STAT3, but no e vidence of a direct interaction was provided.  
Interestingly, the control C151 construct occasionally had an intermediate suppressive 
effect on the incidence and clinical severity of disease in a collagen-induced arthritis 
model (159).  Though not significant, these findings raise the possibility that some of the 
anti-inflammatory effects observed in this model are again due to sequence-independent 
PS backbone effects.   
Other mechanisms of action have also been proposed for sup ODNs.  A recent 
report found that inversion of the cytosine and guanine residues in the CpG motif to a 
GpC configuration also conferred suppressive properties in a model of type I 
hypersensitivity reaction (160).  Interestingly, GpC-mediated suppression was dependent 
on activation of the TLR7-TRIF signaling pathway leading to noncanonical NF-κB 
activation and the induction of TGF-β and indoleamine 2,3-dioxygenase (IDO).  In 
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addition, a PS construct composed of poly(dT) was shown to prevent TLR7-mediated 
signaling, but enhance TLR8 signaling.  This study revealed that administration of 
poly(dT) abolished NF-κB activation in TLR7-expressing HEK 293 cells stimulated with 
the imidazoquinoline derivative Resiquimod (R-848) (161). However, it enhanced R-848-
driven NF-κB activation in TLR8-expressing HEK 293 cells.  Moreover, treatment of 
human PBMCs shifted the cytokine profile from TLR7-mediated IFN-α production, 
towards TLR8-mediated IL-12 and TNF-α production.  Thus, alternative mechanisms to 
TLR9 inhibition have been demonstrated.  These studies have revealed the truly complex 
and cell-type specific effects sup ODNs can generate.  Though the immunoregulatory 
impact of sup ODNs in experimental models is impressive, and the applications appear 
broad, how these effects are mediated is not well understood.  Investigation into the 
precise mechanisms of action of sup ODNs is a priority that may one day make tailored 
therapeutic intervention in human disease possible.   
 
 
1.4 Herpesviruses 
 
Herpesviruses are a family of enveloped DNA viruses that cause widespread disease in 
humans and animals.  All have large dsDNA genomes, replicate within the host nucleus 
and can establish both lytic and latent forms of infection.  The family Herpesviridae is 
divided into three subfamilies the Alphaherpesvirinae, Betaherpesvirinae and 
Gammaherpesvirinae.  The alpha herpesviruses include herpes simplex virus-1 (HSV-1, 
also known as human herpes virus-1; HHV-1), herpes simplex virus-2 (HSV-2; HHV-2) 
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and varicella-zoster virus (VZV; HHV-3).  Alpha herpesviruses are known for their short 
replication cycle as well as their ability to latently infect neurons.  Though they are only 
found naturally in humans, alpha herpesviruses can infect a broad range of hosts.  The 
beta herpesviruses include roseolovirus (HHV-6), pityriasis rosea (HHV-7), human 
cytomelagovirus (HCMV; HHV-5) and murine cytomegalovirus (MCMV).  V iruses of 
the beta subfamily have longer replication cycles than the alphaherpesviruses and 
establish latency in lymphocytes.  In addition, their host range is narrow and often 
species-specific.  T he gamma herpesviruses include Epstein-Barr virus (EBV; HHV-4) 
and Kaposi’s sarcoma-associated herpesvirus (KSHV).  M ost gamma herpesviruses 
establish latency in B cells and, as such, are associated with the development of a number 
of lymphoproliferative disorders.  The discussion below focuses on H SV-1, it’s virion 
structure, infectious pathophysiology and the innate response. 
 
1.4.1  Herpes Simplex Virus type 1 
 
HSV-1, a member of the alpha herpesviridae subfamily, consists of a large linear 
double-stranded DNA genome housed within an icosahedral capsid surrounded by a lipid 
envelope.  T he tegument, which is composed of as many as 20 di fferent proteins, lies 
between the capsid and envelope.  The HSV-1 genome is 152 kb in length and encodes 
upwards of 84 p roteins.  H ost RNA polymerase II transcribes genes from the viral 
genome in three distinct stages resulting in immediate-early (2-4 hrs post-infection), early 
(5-7 hrs), and late (stage dependent) transcripts (162).  T he immediate-early genes are 
involved in host transcription shut-off, immune evasion and regulation of later viral 
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genes.  The early genes function largely to subvert host cellular machinery and replicate 
the genome but include some minor structural proteins.  The late genes encode most of 
the structural components of the virion.  V iral entry is mediated by a group of 
glycoproteins (gC, gD, gH, gL, gB) found on the viral envelope (162).  Upon entry, the 
capsid is transported along microtubules to the nucleus where the viral genome is injected 
through a nuclear pore.  In the nucleus, the viral genome circularizes and enters the lytic 
cycle or establishes latent infection.  During the lytic cycle, the genome replicates and 
viral particles are assembled within the nucleus, then bud outward.  T he final viral 
envelope is obtained by budding into cytoplasmic vesicles within the host cell.  HSV-1 
most commonly enters the latent phase in the sensory neurons of the trigeminal and/or 
olfactory ganglia.  D uring this time the Latency Associated Transcript (LAT) is 
expressed and acts to silence lytic cycle genes.  HSV-1 can be reactivated from its latent 
state by a variety of stimuli and, therefore, represents a lifelong repository. 
 
1.4.2  HSV-1, the pathogen and pathophysiology 
 
HSV-1 is an old and extremely successful pathogen affecting more than one-third 
of the world’s population.  The seroprevalence of HSV-1 increases with age and ranges 
between 65-90% depending on gender and ethnicity (163).  HSV-1 enters the human 
body through the mucosal membranes or lesions in the skin.  Replication takes place 
initially in epithelial cells resulting in localized infection that can be subclinical or 
manifest as vesicular lesions.  HSV-1-infected cells undergo apoptosis or are lysed by 
immune cells and the resulting intradermal cellular debris and inflammatory exudate 
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causes the prototypical vesicles known colloquially as “cold sores”.  In certain 
circumstances, HSV-1 can disseminate and replicate in other anatomical locations 
including the liver, lung and central nervous system causing severe illness (164, 165).  
These life-threatening manifestations are rare and more commonly observed in 
immunocompromised individuals.  The key to HSV-1’s success derives from its ability to 
latently infect neurons.  From this location, it is reactivated by stress, UV-light or trauma 
and transported down axons to the periphery where it re-enters the lytic cycle replicating 
in epithelial cells (166).  B etween outbreaks, HSV-1 is essentially immunologically 
silent.  Even when infectious individuals may display no symptoms resulting in 
horizontal transmission.  In addition to latency HSV-1 has devised a number of strategies 
to evade the immune system.  Certain viral proteins function to inhibit the production of 
IFN, cytokines and chemokines, downregulate MHC presentation and induce apoptosis in 
innate immune cells (166-168).  HHV infected cell polypeptide 0 (ICP0), an immediate-
early protein, disrupts promyelocytic leukemia bodies, inhibits the activity of IRF3 and 
IRF7, and degrades MyD88 (168-170).  Despite this the immune system is usually 
successful in clearing lytic infections and suppressing reactivation. 
 
1.4.3 Role of innate immunity in recognizing HSV-1 
 
Control of HSV-1 infection requires both innate and adaptive arms of the immune 
system.  Production of cytokines, chemokines and Type I IFNs by the innate immune 
system is vital for early viral control.  These effectors directly block viral replication and 
reduce cell-to-cell transmission by inducing enzymes such as PKR and RNAse L.  They 
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also recruit additional leukocytes, increase MHC presentation and activate lymphocytes, 
coordinating the adaptive response that is required for complete viral clearance.  Innate 
immune cells detect HSV-1 infection through several classes of PRRs including the 
TLRs, RLRs and cytosolic DNA sensors.  TLR3, TLR9 and the TLR2/6 heterodimer 
have all been implicated in the immune response to HSV-1.  In plasmacytoid dendritic 
cells, TLR9 is activated by unmethylated CpG motifs in the HSV-1 genomic DNA and is 
chiefly responsible for type I IFN induction at early time points (171).  Interestingly a 
second wave of type I IFN is produced by monocytes, macrophages and conventional 
dendritic cells (CDCs) and is TLR9- and MyD88-independent but requires replication 
competent virus (171).  This second wave is likely due to cytosolic sensors and may 
explain why survival and viral burdens are unchanged in TLR9 knockout mice 
challenged with HSV-1 (172, 173).  Alternatively TLR9 signaling may be more 
important in certain manifestations of HSV-1 induced disease.  A  recent study showed 
TLR9-deficient mice had higher rates of mortality and viral replication when challenged 
intranasally with HSV-1 (174).  Thus, TLR9’s precise role in HSV pathogenesis and the 
relative contributions of other PRRs requires further investigation 
TLR2 is expressed by a wide variety of immune and non-immune cells including 
monocytes, macrophages, microglia, dendritic cells, neutrophils and epithelial cells (175, 
176).  T he TLR2/6 heterodimer recognizes an undefined HSV-1 component, which 
stimulates the production of cytokines and chemokines by microglia (177, 178).  
However, rather than having a protective role, recent studies have shown TLR2 signaling 
in microglia contributes to the immunopathology of HSV-1 encephalitis (HSE) (178).  
TLR3 recognizes double stranded RNA produced during HSV replication (7).  T his 
 36 
appears to be especially important in HSE as patients with TLR3 dominant-negative 
mutations display increased susceptibility (179). 
Double stranded RNA produced during HSV-1 infection has been shown to 
activate RIG-I and MDA5 (171).   Activation of these RNA helicases and recruitment of 
mitochondrial antiviral-signaling protein (MAVS) results in type I IFN production in 
macrophages (171).  As discussed previously, a number of cytosolic DNA receptors have 
also been implicated in the Type I IFN response to HSV-1 including DAI, DDX41, IFI16 
and cGAS.  Our understanding of these cytosolic receptors is rapidly expanding but the 
precise contribution of each to the HSV-1 response is still debated.  Whether they signal 
collaboratively or function in a cell type-specific manner is still unknown.  Interestingly, 
recent research suggests IFI16 detects HSV-1 DNA within the nucleus and, thus, may be 
uniquely positioned to detect viral genome replication (180). 
The importance of IL-1β in the response to HSV-1 has been clearly established 
(177).  However, receptors responsible for inflammasome formation in response to HSV-
1 are poorly understood.  A recent study has suggested HSV-1 may assemble an 
inflammasome through the IFI16 and NLRP3 receptors.  T his paper demonstrated that 
after HSV-1 infection, IFI16 and NLRP3 associated with ASC in human foreskin 
fibroblasts (181).  H owever, this study failed to observe detectable levels of IL-1β 
secretion following HSV-1 infection.  Instead, the authors found that HSV-1 induced the 
rapid degradation of IFI16 and hypothesized that trapping of caspase-1 in actin clusters 
prevented cytokine processing downstream of NLRP3 (181).  Thus, additional studies are 
needed to define the contributions of these receptors to inflammasome formation 
following HSV-1 infection. 
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1.5  Dissertation Objectives 
 
This dissertation has two main focuses.  T he first is to explore the role of 
suppressive oligodeoxynucleotides in cytoplasmic receptor signaling.  The second is to 
define the pathways responsible for IL-1β and IL-18 induction and maturation in 
response to HSV-1 infection. 
 
Objectives: 
 
1.1) Investigate the effects of sup ODNs on cytosolic receptor-mediated signaling.  
Using primary mouse cell lines and human cell lines, we tested the inhibitory 
effects of A151 on TLR4, RIG-I, NLRP3, AIM2 and interferon-inducing 
cytosolic receptors.  We demonstrated that A151 mediates specific inhibition of 
DNA sensing pathways.  U sing Nanostring analysis, we defined the broad 
inhibitory potential of A151 on inflammation. 
1.2) Explore construct potency and define the contributions of sequence and 
backbone.  Using the C151 and A151 and equivalent phosphodiester constructs, 
we explored the effects of backbone chemistry and sequence on inhibition.  We 
found that the phosphorothioate backbone was essential for inhibition.  In 
addition, we discovered differential sequence requirements for maximal inhibition 
of IFN-inducing cytosolic signaling versus inflammasome signaling. 
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1.3) Identify the mechanisms of inhibition.  Using biotinylated A151 and C151, we 
explored the association of these constructs with different cytosolic pattern 
recognition receptors.  We found that sup ODN affinity correlated with inhibitory 
potency, while A151 pulled down more AIM2, C151 pulled down more IFI16.  
Mechanistically, we discovered that A151 prevented ASC recruitment to AIM2 
and assembly of the inflammasome complex. 
 
2.1) Define the signal pathway(s) responsible for HSV-1 induction of pro-IL-1β and 
pro-IL-18.  We found that the TLR2-MyD88 signaling pathway was essential for 
pro-IL-1β expression in macrophages and DCs.  In contrast, pro-IL-18 expression 
was dependent on synergy between MyD88 and STING pathways. 
2.2)  Define the receptor responsible for inflammasome assembly in response to HSV-1 
infection.  Primary mouse cells deficient in NLRP3, NLRP12, ASC and caspase-1 
were used to explore inflammasome formation.  We demonstrated that NLRP3 is 
responsible for IL-1β maturation in dendritic cells and macrophages.  However, 
neutrophils relied on NLRP12 for maturation of IL-1β. 
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 40 
Chapter II  
 
Suppressive oligodeoxynucleotides inhibit cytosolic DNA sensing pathways 
 
Abstract 
 
Synthetic oligodeoxynucleotides comprised of the immunosuppressive motif 
TTAGGG block TLR9 signaling, prevent STAT1 and STAT4 phosphorylation and 
attenuate a variety of inflammatory responses in vivo.  Here, we demonstrate that such 
suppressive oligodeoxynucleotides (sup ODN) also abrogate activation of cytosolic 
deoxyribonucleic acid sensing pathways.  Pretreatment of dendritic cells and 
macrophages with the suppressive ODN-A151 abrogated type I IFN, TNF-α and ISG 
induction in response to cytosolic dsDNA.  A151 also reduced IFN-β and TNF-α 
induction in BMDC and BMDM in response to the herpesviruses HSV-1 and MCMV, 
but had no effect on the responses to LPS or Sendai virus.  In addition, A151 abrogated 
caspase-1-dependent IL-1β and IL-18 maturation in dendritic cells stimulated with 
dsDNA and MCMV.  Although inhibition of IFN-inducing pathways and inflammasome 
assembly was dependent on backbone composition, the nucleotide content differentially 
affected these pathways.  While A151 more potently suppressed the AIM2 
inflammasome, a related construct, C151 proved to be a more potent inhibitor of IFN 
induction.  A151 suppressed inflammasome signaling by binding to AIM2 and competing 
with immune-stimulatory DNA.  T he interaction of A151 and AIM2 prevented 
recruitment of the adapter ASC and assembly of the macromolecular inflammasome 
complex.  Collectively, these findings reveal a n ovel mechanism by which suppressive 
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ODNs modulate the immune system and unveil novel applications for suppressive ODNs 
in the treatment of infectious and autoimmune diseases. 
 
Introduction 
 
The innate immune system provides an essential first line of defense against 
infection.  Innate immune cells detect pathogens through distinct classes of Pattern 
Recognition Receptors (PRR) including the Toll-like receptors (TLRs), the C-type lectin 
receptors (CLRs), the RIG-like helicases (RLRs), the NOD-like receptors (NLRs) and the 
PYHIN receptors.  T hese PRRs respond to conserved pathogen and danger-associated 
molecular patterns (PAMPs/DAMPs) allowing rapid recognition and response to 
infectious agents.  A ctivated receptors initiate signaling cascades that lead to the 
production of cytokines, chemokines and type I interferons, all of which are vital for 
controlling pathogen loads directly and coordinating adaptive immune responses.  
Unrestricted or improper activation of the innate immune system can have dire 
consequences.  Uncontrolled inflammation can cause extensive tissue damage, exacerbate 
septic shock and contribute to the development of autoimmune diseases (182, 183).  
Thus, a balance between activation and suppression must be struck to ensure an 
appropriate and effective innate response.   
Detection of DNA by the innate immune system is an important mechanism by 
which pathogens are recognized in order to activate protective immunity.  Recognition of 
DNA is complex and can be influenced by a variety of factors including sequence, 
secondary structure, subcellular localization and covalent modification.  Hypomethylated 
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CpG motifs found in bacteria and certain viruses are detected in the endosomal 
compartment by TLR9 (8, 184).  In contrast, a number of DNA sensors have been 
implicated in cytosolic dsDNA sensing including Gamma-interferon-inducible protein-16 
(IFI16) and Absent in melanoma-2 (AIM2): two members of the PYHIN protein family, 
DDX41; a member of the DEXDc helicase family and cGAS; a r ecently identified 
nucleotidyltransferase (16, 17, 46-48, 55). 
IFI16 was first identified as a potential intracellular DNA sensor in a screen using 
a 70 bp DNA motif derived from the Vaccinia virus (VACV) genome to affinity purify 
binding partners. Unterholzner et al. found that IFN-β induction by this VACV 70mer 
was independent of TLR, DAI and Pol III signaling but was attenuated following IFI16 
knockdown (70).  Further analysis revealed IFI16 also mediated IFN-β induction 
following transfection with a 60bp m otif derived from the HSV genome as well as by 
HSV-1 infection.  Similarly, targeting the IFI16 murine ortholog p204 attenuated IFN-β 
and TNF-α production in response to these dsDNA motifs and in HSV-1 infection, 
suggesting a role in both IRF3 and NF-κB-dependent inflammatory pathways.  IFI16 
mediated this response by engaging the crucial signaling component STING leading to 
the activation of TBK1 and nuclear translocation of IRF3 and p65 (70).  Both IFI16 and 
p204 contain a DNA-binding HIN200A and HIN200B domain as well as a pyrin (PYD) 
domain (71, 72).  In macrophages, cytosolic IFI16 may be exposed to HSV-1 genomic 
DNA following proteasomal degredation of the HSV-1 capsid (185).  Recently IFI16 has 
also been shown to sense HSV-1 DNA within the nucleus and signal via STING through 
an unknown intermediate (186).  In contrast to IFI16, another member of the PYHIN 
family, AIM2 signals via assembly of an inflammasome. 
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The inflammasome is a large complex that provides a platform for the activation 
of caspase-1, an enzyme that cleaves the immature interleukins pro-IL-1β and pro-IL-18 
into their active forms.  There are distinct types of inflammasomes, differentiated by their 
protein constituents and activating receptors.  In many cases, an inflammasome contains a 
nucleotide binding and oligomerization leucine-rich repeat (NLR) protein.  In addition, 
our lab and others have recently reported that the cytosolic PYHIN family member, 
Absent in melanoma-2 (AIM2), directly binds to cytosolic bacterial and viral double-
stranded DNA leading to the formation of an AIM2 inflammasome complex (16, 17, 125, 
126).  The AIM2 inflammasome is activated in response to infection by bacteria such as 
Listeria monocytogenes as well as the viral pathogen murine cytomegalovirus (MCMV) 
where it p lays an essential role in controlling early viral replication (16).  AIM2 is 
composed of a DNA-binding HIN200C domain and a PYD domain, which recruits 
caspase-1 via the adapter molecule apoptotic speck protein with CARD domain (ASC) 
(17, 46, 125, 126, 187).  
Certain DNA sequences such as the TTAGGG repeat commonly found in 
mammalian telomeric DNA have been shown to suppress innate immune activation.  The 
therapeutic potential of these suppressive oligodeoxynucleotides (sup ODN) have been 
demonstrated in murine models of inflammatory arthritis, toxic shock, systemic lupus 
erythematosus, atherosclerosis and silica-induced pulmonary inflammation (151-153, 
155, 188).  Given the known roles for type I IFN and the pro-inflammatory cytokines, IL-
1β and IL-18, in the development of many of these diseases, we set out to examine the 
effect of sup ODNs on cytosolic innate immune sensors (189).  Synthetic sup ODNs were 
first thought to prevent TLR9 activation by binding to unmethylated CpG DNA (149).  
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However, other studies suggest rather than interacting with CpG ODNs, they likely 
compete for binding to TLR9 (148).  Interestingly, the potency of these sup ODNs was 
found to be strongly affected by sequence, a phenomenon not explained by their relative 
avidity to the TLR9 ectodomain (148).  In addition, Shirota et al. have shown that sup 
ODNs prevent Th1 differentiation in wild-type and TLR9-deficient CD4+ cells alike, 
suggesting that their biological activity may be independent of their interaction with 
TLR9 and, instead, involves as yet undefined receptor(s) (154).  H ere we demonstrate 
that treatment with the sup ODN A151, a ssDNA construct composed of four repeats of 
the hexanucleotide TTAGGG motif, blocks cytosolic DNA-driven IFN and inflammatory 
cytokine production.  A 151 specifically inhibited the AIM2 inflammasome and had no 
effect on NLRP3-mediated inflammasome activation, RIG-I or LPS signaling.  T he 
inhibitory effect of A151 was dependent on both its phosphorothioate (PS) backbone and 
sequence.  S ubstitution of the guanine triplet in A151 for adenine residues (C151) 
reduced the potency of AIM2 inflammasome suppression by 94% (Table 2.1).  Our data 
indicate that A151 functions as an inhibitor by competing with stimulatory DNA ligands 
for AIM2 binding.  Intriguingly, C151 proved to be a more potent inhibitor of interferon-
inducing pathways.  In support of a competitive model of inhibition, IFI16 bound more 
strongly to the C151 construct.  Interaction with members of the IFI20X/IFI16 (PYHIN) 
receptor family may account for many of the previously unexplained anti-inflammatory 
effects of sup ODNs.  Collectively, these observations suggest a novel mechanism for sup 
ODN-mediated inhibition of the innate immune system. 
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Table 2.1 : Oligodeoxyribonucleotide Construct Sequences 
      
      
                      
Name              Sequence    
 
A151  5'-TTAGGGTTAGGGTTAGGGTTAGGG-3'  
 
C151  5'-TTCAAATTCAAATTCAAATTCAAA-3'  
 
2114  5'-TCCTGGAGGGGAAGT-3'   
 
4348  5'-TCGTATCCTGGAGGGGAAG-3'   
 
1826  5'-TCCATGACGTTCCTGACGTT-3'   
 
10104  5'-TCGTCGTTTCGTCGTTTTGTCGTT-3'  
 
2336  5'-GGGgacgacgtcgtcgGGGGG-3'   
      
 
* Capitalized nucleotides are connected by phosphorothioate linkages 
lower case nucleotides have 5'-phosphdiester linkages 
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Results 
 
A151 has broad anti-inflammatory activities against cytosolic DNA sensing 
pathways.  
 A number of studies have explored the effects of the sup ODN A151 on type I IFN 
and cytokine production following LPS and CpG ODN stimulation (149, 151, 153) .  
However, these studies often have a l imited scope, only reporting A151’s effects on a  
handful of inflammatory molecules.  T o examine its immunosuppressive potential, we 
measured the response of bone marrow-derived dendritic cells (BMDC) to A151 
treatment alone and explored whether it affected induction of innate response genes 
following stimulation with synthetic dsDNA poly(dA:dT) and LPS.  T otal RNA was 
isolated from cells and mRNA levels of a panel of cytokines, chemokines, PRRs and 
signal transduction molecules were measured by multiplex gene expression analysis 
using nCounter (Nanostring) technology (Fig. 2.1 and Table 2.2).  Nanostring analysis 
utilizes fluorescently coded probes that hybridize directly to target mRNA, allowing each 
individual mRNA to be counted without the need for amplification (190).  This allows 
the detection of many targets simultaneously in a highly sensitive manner particularly 
when examining mRNAs present at low levels.  This analysis revealed, resting BMDC 
expressed particularly high mRNA levels of TLR2 and TLR4 as well as a number of 
other receptors including TLR3, TLR7, TLR8, AIM2, IFI204, NLRP3, RIG-I and MDA-
5.  Molecules involved in signal transduction such as NF-κB, IκBα, MyD88, IRF2, IRF5, 
STAT3 and STAT1 and the cysteine protease caspase-1 were also expressed at basal 
levels.  Untreated BMDC displayed very low levels of Type I IFN expression.  Treatment 
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Table 2.2 : Nanostring Normalized mRNA Counts  
Gene   Stimulation   
 Media A151 LPS LPS + A151 p(dA:dT) p(dA:dT) + A151 
       
Cyokines, chemokines and their receptors    
Ifna4 3 3 14 14 463 15 
Ifnb1 5 2 125 121 11674 121 
Ifng 2 2 3 1 4 2 
Il-1a 2299 3845 90032 85988 22190 3824 
Il-1b 513 1190 96483 97982 9166 1610 
Il-4 1 2 10 5 7 2 
Il-6 12 31 27868 25706 3602 72 
Il-10 1 1 18 19 1 1 
Il-12a 2 3 73 78 4 1 
Il-12b 7 17 9342 8241 360 22 
Il-13 1 1 4 10 4 1 
Il-15 37 49 283 254 157 49 
Il-18 2293 1977 3796 3353 1698 1494 
Il-21 2 1 1 2 1 1 
Il-23a 2 3 417 478 43 1 
Il-33 8 8 30 31 42 11 
Il-1ra 18886 20912 74120 69265 49214 22396 
ccl4 729 567 59040 55448 31622 1012 
ccl5 733 709 41138 36889 6854 758 
cxcl1 33 37 13628 12750 756 40 
cxcl10 26 36 8505 6490 29161 1336 
ccr1 2534 2204 1397 1147 2389 2358 
ccr2 169 181 22 13 96 128 
cxcl2 158 213 29228 28712 3783 294 
cxcl6 440 502 2680 2314 598 413 
cxcl9 5 7 182 166 453 23 
tgfb1 8108 8788 10811 10902 8657 7987 
tgfb2 13 15 22 27 33 13 
tnfa 671 1112 30224 29787 15646 1705 
       
PRRs, downstream signaling components    
aim2 439 452 417 387 1058 412 
IrakM 612 761 3917 3668 559 586 
nlrc4 413 455 650 631 358 402 
nlrc5 77 70 227 176 338 93 
nlrp12 1 1 3 7 6 4 
nlrp3 373 482 5471 5323 1232 498 
nlrp6 4 9 7 6 7 4 
Ifi204 99 110 1079 762 1910 251 
Ifi205 8 10 1903 1520 1541 70 
Ifi47 107 117 2374 1477 2716 380 
Ifit1 11 20 6927 5165 17556 558 
Ifit2 24 15 1573 1129 5953 248 
casp1 1014 1022 1454 1354 1654 956 
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 Media A151 LPS LPS + A151 p(dA:dT) p(dA:dT) + A151 
mnda 28 24 1412 1180 894 136 
mndal 257 315 12079 11466 5305 515 
myd88 883 908 1696 1494 1648 1012 
lgp2 166 186 892 683 1042 313 
tlr1 25 42 82 131 15 30 
tlr11 6 6 4 4 6 4 
tlr2 3386 5074 17166 16029 11960 5878 
tlr3 148 157 182 132 353 155 
tlr4 4290 3557 1062 918 3292 2934 
tlr5 5 3 3 4 1 3 
tlr7 1044 952 2299 2332 1100 1021 
tlr8 1663 1368 931 838 1530 1164 
tlr9 33 31 30 18 50 30 
rig-i 203 182 1519 1127 1968 423 
mda5 264 273 6257 4983 4781 409 
IkBa 3773 5889 16694 17159 12996 5520 
unc93b 2894 2907 2336 2339 2957 2950 
md2 606 589 808 697 485 552 
pstpip1 155 163 80 64 148 130 
rybp 184 194 348 286 247 178 
viperin 50 41 10291 6942 26101 1202 
yaf2 573 476 413 364 457 395 
zbp1 49 43 728 523 868 110 
       
Transcription factors      
Irf1 492 578 4671 3850 9365 1398 
Irf2 959 977 803 659 1445 911 
Irf5 944 1129 928 940 1580 1077 
Irf7 31 26 988 625 1814 316 
nfkb1 932 1147 5666 5262 1772 973 
nfkb2 1384 1977 10479 10426 2600 1965 
stat1 524 447 1452 1039 2253 770 
stat3 1256 1140 1226 1102 1281 983 
eya4 21 35 8 13 24 24 
       
Proinflammatory enzymes     
arg1 12 26 22 13 28 29 
arg2 123 126 806 734 168 99 
cox2 114 53 22628 20632 911 92 
nos2 7 7 226 202 39 10 
oas2 29 26 268 172 398 93 
mmp2 223 229 472 486 247 202 
trex1 530 617 6935 6281 7037 1924 
adar 590 575 1799 1394 1681 725 
samhd1 2132 2288 1693 1415 5494 2122 
       
Cell adhesion and activation markers    
cd18 683 720 633 612 555 562 
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 Media A151 LPS LPS + A151 p(dA:dT) p(dA:dT) + A151 
cd40 100 105 3018 2967 497 110 
cd80 363 357 466 438 560 255 
cd86 217 229 440 402 625 267 
Icam1 1900 2698 9348 9528 4851 3112 
       
Anti-inflammatory signaling components    
socs1 168 142 737 812 1108 304 
socs3 516 720 3807 3924 2200 961 
duba 866 923 1295 1193 994 809 
dusp6 624 591 514 477 446 464 
a20 433 750 12997 13020 6293 766 
prdm1 90 123 292 332 343 112 
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Table 2.3 : Nanostring mRNA Fold Induction Compared to Media 
Gene      Stimulation    
 A151 / Media LPS / Media p(dA:dT) / Media   
Ifnb1 0.4 24.2 2253.6   
Ifit1 1.8 607.1 1538.7   
cxcl10 1.4 328.1 1125.0   
viperin 0.8 206.8 524.4   
Il6 2.5 2240.2 289.6   
Ifit2 0.6 66.0 249.6   
Ifi205 1.2 229.3 185.6   
Ifna4 1.1 4.4 148.8   
cxcl9 1.3 35.2 87.4   
Irf7 0.8 31.7 58.3   
Il12b 2.3 1286.7 49.6   
ccl4 0.8 81.0 43.4   
mnda 0.8 50.4 31.9   
Ifi47 1.1 22.2 25.4   
cxcl2 1.4 185.4 24.0   
tnfa 1.7 45.0 23.3   
cxcl1 1.1 410.7 22.8   
Il23a 1.6 201.4 20.6   
mndal 1.2 47.0 20.6   
Ifi204 1.1 11.0 19.4   
Irf1 1.2 9.5 19.1   
mda5 1.0 23.7 18.1   
Il-1b 2.3 188.0 17.9   
zbp1 0.9 14.9 17.8   
a20 1.7 30.0 14.5   
oas2 0.9 9.2 13.7   
trex1 1.2 13.1 13.3   
rig-i 0.9 7.5 9.7   
Il-1a 1.7 39.2 9.7   
ccl5 1.0 56.1 9.3   
cox2 0.5 198.4 8.0   
Il-4 2.2 9.2 7.0   
socs1 0.8 4.4 6.6   
lgp2 1.1 5.4 6.3   
nlrp12 1.1 3.1 5.9   
nos2 0.9 31.1 5.4   
Il-33 1.0 3.6 5.0   
cd40 1.1 30.3 5.0   
nlrc5 0.9 3.0 4.4   
stat1 0.9 2.8 4.3   
socs3 1.4 7.4 4.3   
Il15 1.3 7.6 4.2   
prdm1 1.4 3.2 3.8   
tlr2 1.5 5.1 3.5   
Il13 1.1 4.1 3.5   
IkBa 1.6 4.4 3.4   
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 A151 / Media LPS / Media p(dA:dT) / Media   
nlrp3 1.3 14.7 3.3   
cd86 1.1 2.0 2.9   
adar 1.0 3.0 2.8   
Il1ra 1.1 3.9 2.6   
samhd1 1.1 0.8 2.6   
Icam1 1.4 4.9 2.6   
tgfb2 1.1 1.7 2.4   
aim2 1.0 1.0 2.4   
tlr3 1.1 1.2 2.4   
arg1 2.1 1.8 2.3   
nfkb1 1.2 6.1 1.9   
nfkb2 1.4 7.6 1.9   
myd88 1.0 1.9 1.9   
Ifng 1.1 1.5 1.8   
Il12a 1.6 35.4 1.8   
nlrp6 2.2 1.8 1.8   
Irf5 1.2 1.0 1.7   
casp1 1.0 1.4 1.6   
cd80 1.0 1.3 1.5   
tlr9 0.9 0.9 1.5   
Irf2 1.0 0.8 1.5   
arg2 1.0 6.5 1.4   
cxcl6 1.1 6.1 1.4   
rybp 1.1 1.9 1.3   
eya4 1.7 0.4 1.2   
Il-10 1.1 17.3 1.2   
duba 1.1 1.5 1.1   
mmp2 1.0 2.1 1.1   
tgfb1 1.1 1.3 1.1   
tlr7 0.9 2.2 1.1   
unc93b 1.0 0.8 1.0   
stat3 0.9 1.0 1.0   
tlr11 0.9 0.7 1.0   
pstpip1 1.1 0.5 1.0   
ccr1 0.9 0.6 0.9   
tlr8 0.8 0.6 0.9   
IrakM 1.2 6.4 0.9   
nlrc4 1.1 1.6 0.9   
cd18 1.1 0.9 0.8   
md2 1.0 1.3 0.8   
yaf2 0.8 0.7 0.8   
tlr4 0.8 0.2 0.8   
Il-18 0.9 1.7 0.7   
dusp6 0.9 0.8 0.7   
Il21 0.5 0.5 0.6   
tlr1 1.7 3.3 0.6   
ccr2 1.1 0.1 0.6   
tlr5 0.7 0.6 0.2   
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Table 2.4 : Nanostring mRNA Fold Reduction by A151 Treatment 
Gene  Stimulation  
 LPS / (LPS + A151) p(dA:dT) / p(dA:dT) + A151  
Ifnb1 1.0 96.3  
Il6 1.1 50.0  
Ifit1 1.3 31.5  
ccl4 1.1 31.2  
Ifna4 1.0 30.0  
Il23a 0.9 29.1  
Ifit2 1.4 24.0  
Ifi205 1.3 22.1  
cxcl10 1.3 21.8  
viperin 1.5 21.7  
cxcl9 1.1 19.9  
cxcl1 1.1 18.7  
Il12b 1.1 16.3  
cxcl2 1.0 12.9  
mda5 1.3 11.7  
mndal 1.1 10.3  
cox2 1.1 9.9  
tnfa 1.0 9.2  
ccl5 1.1 9.0  
a20 1.0 8.2  
zbp1 1.4 7.9  
Ifi204 1.4 7.6  
Ifi47 1.6 7.1  
Irf1 1.2 6.7  
mnda 1.2 6.6  
Il-1a 1.0 5.8  
Irf7 1.6 5.7  
Il-1b 1.0 5.7  
Il12a 0.9 4.9  
Il13 0.4 4.9  
rig-i 1.3 4.6  
cd40 1.0 4.5  
oas2 1.6 4.3  
nos2 1.1 3.8  
Il-33 1.0 3.8  
trex1 1.1 3.7  
socs1 0.9 3.7  
nlrc5 1.3 3.7  
lgp2 1.3 3.3  
Il-4 1.8 3.3  
Il15 1.1 3.2  
prdm1 0.9 3.1  
stat1 1.4 2.9  
samhd1 1.2 2.6  
aim2 1.1 2.6  
tgfb2 0.8 2.5  
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 LPS / (LPS + A151) p(dA:dT) / p(dA:dT) + A151  
nlrp3 1.0 2.5  
IkBa 1.0 2.4  
cd86 1.1 2.3  
adar 1.3 2.3  
socs3 1.0 2.3  
tlr3 1.4 2.3  
Il1ra 1.1 2.2  
cd80 1.1 2.2  
tlr2 1.1 2.0  
nlrp6 1.2 2.0  
nfkb1 1.1 1.8  
casp1 1.1 1.7  
arg2 1.1 1.7  
tlr9 1.7 1.7  
nlrp12 0.4 1.7  
Ifng 3.0 1.7  
Il21 0.5 1.6  
myd88 1.1 1.6  
Irf2 1.2 1.6  
Icam1 1.0 1.6  
Irf5 1.0 1.5  
cxcl6 1.2 1.4  
rybp 1.2 1.4  
tlr11 1.0 1.4  
nfkb2 1.0 1.3  
tlr8 1.1 1.3  
stat3 1.1 1.3  
duba 1.1 1.2  
mmp2 1.0 1.2  
yaf2 1.1 1.2  
Il-18 1.1 1.1  
pstpip1 1.2 1.1  
tlr4 1.2 1.1  
tgfb1 1.0 1.1  
tlr7 1.0 1.1  
eya4 0.7 1.0  
ccr1 1.2 1.0  
unc93b 1.0 1.0  
cd18 1.0 1.0  
arg1 1.8 1.0  
dusp6 1.1 1.0  
IrakM 1.1 1.0  
nlrc4 1.0 0.9  
md2 1.2 0.9  
Il-10 0.9 0.8  
ccr2 1.8 0.8  
tlr1 0.6 0.5  
tlr5 0.8 0.4  
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with A151 alone had very little effect on the transcriptional profile of BMDC (Fig. 2.1 
and Table 2.2).  In keeping with previous reports, A151 treatment did not induce anti-
inflammatory molecules such as IL-10, TGF-β or SOCS3 (146).  By comparison, 
treatment with the synthetic dsDNA ligand poly(dA:dT) drastically increased mRNA 
levels of inflammatory cytokines, type I IFNs and ISGs as well as other immune 
mediators and regulators.  IFN-β, the most highly induced gene, was upregulated more 
than 2000-fold and IL-6 more than 250-fold (Fig. 2.1 and Table 2.3).  Importantly, 
treatment with A151 greatly attenuated the response to poly(dA:dT) (Fig. 2.1 and Table 
2.4).  G enes such as IFN-β and IL-6, which were among the most highly induced by 
poly(dA:dT), were also the most potently suppressed by A151.  Like poly(dA:dT), LPS 
stimulated increased mRNA levels of a variety of cytokines and Type I IFN.  IL-6, the 
most highly induced mRNA by LPS, was increased over 2000-fold (Table 2.3).  In 
contrast to A151’s effects on poly(dA:dT) signaling, A151 did not mitigate LPS-induced 
responses (Fig. 2.1 and Table 2.4).  Thus, A151 appears to have very little effect on the 
expression profile of resting cells and cells treated with LPS, but potently and broadly 
inhibits activation by poly(dA:dT). 
 
A151 and C151 inhibit IFN-β and TNF-α production in response to HSV-1 and 
MCMV.  
 To define the specificity of A151-mediated suppression, BMDC and bone marrow-
derived macrophages (BMDM) were exposed to the herpesviruses HSV-1 or MCMV and 
IFN-β expression was measured by qRT-PCR (Fig. 2.2a,b).  P re-treatment with A151 
reduced IFN-β induction in response to HSV-1 and MCMV in BMDC and BMDM.  
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Interestingly pre-treatment with the C151 construct, in which the guanine residues of 
A151 had been replaced with adenine residues, had a nearly identical suppressive effect.  
In contrast, the IFN-β response to LPS and Sendai virus, a paramyxovirus that activates 
the RIG-I pathway, was unchanged by these constructs (Fig. 2.2a,b).  Similarly, BMDC 
pretreated with A151 and C151 reduced TNF-α mRNA induction in response to HSV-1 
and MCMV, but had no effect on TNF-α induction in responses to LPS or Sendai virus 
(Fig 2.2c).  These data suggests A151- and C151-mediated inhibition of IRF3- and NF-
κB-dependent gene induction is specific to challenge with poly(dA:dT) and the 
herpesviruses HSV-1 and MCMV.   
 
Both sequence and backbone composition affect inhibitory activity of sup ODN on 
interferon-inducing pathways. 
 There is some conflict in the literature regarding the role of sequence in mediating 
A151’s inhibitory effects.  Initial reports suggested the guanine residues found within 
A151’s TTAGGG motif played a role in suppression of CpG-induced TLR9 signaling 
(149).  H owever, other groups demonstrated that inhibition is largely independent of 
sequence and, instead, relies on the presence of a phosphorothioate backbone (PS) (146).  
To further explore the role of sequence in suppression, a dose response experiment was 
performed to establish how potently sup ODN inhibited poly(dA:dT) signaling.  
Surprisingly, we found the C151 construct more potently suppressed IFN-β secretion 
than did A151 (Fig 2.3a,b).  In BMDC, C151 was approximately 10-times more potent 
than A151, although at higher concentrations these constructs were equally efficacious.  
The dose requirements for inhibition also varied between macrophages and dendritic 
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Figure 2.2: A lSI and CIS I suppress IFNP and TNFa production in re-.spon.st to poly(dA:dT), 
1-JSV~I and MC MV A. Bl\•IDC and B. BtviDT\•1 were. stimulatt.d with LPS (200 ng/ml). 300 ng of 
poly(dA:dT) complexed with lipofeCiamine 2000, MCMV (MOl I 0), IISV- 1 (MOl I 0), or SV 
(200 I JAU/ml) in the presence or absence of A 151/C ISI (3 .-..rvl) for 4 h. IFN-P and ~-actin mRNA 
was me.as\u·ed by qPCR. IFN-P induction is represented relative to unt•·eated controls. C. Bl\•IDC 
were. stimulated as above. TN F-a and ~ac1in mRNA was mea:mre.d by qPCR. TN F-a induction is 
rt-presentt .d l'elative. to untreate.d cont•·ols. 
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cells.  At a concentration of 3 µM, inhibition of the IFN-β response was near maximal for 
both A151 and C151.  This explains why no differences in suppression were observed in 
earlier experiments.  To assess the effects of the PS backbone on IFN-β secretion BMDM  
and BMDC were treated with A151, C151 and a phosphodiester (PD) version of C151 
(referred to as C151(PD)), followed by transfection with poly(dA:dT) (Fig 2.3c,d).  
Unlike the two PS constructs, C151(PD) failed to block the IFN-β response.  Thus, while 
a PS backbone is essential for suppression, sequence plays a role only when lower doses 
of sup ODN are employed.  In addition to the A151 construct, a number of sup ODN 
have been developed to block TLR9 signaling selectively.  A shman et al. extensively 
documented the sequence requirements for optimal inhibition of TLR9 activation and 
identified a sequence designated 4348 as one of the most potent TLR9 suppressing 
constructs (148).  We explored the relative potency of 4348 on  poly(dA:dT)-induced 
IFN-β secretion using a concentration of 1 µM in BMDC and 0.5 µM in BMDM that 
provided strong suppression, but allowed observation of sequence specific effects.  The 
4348 construct mediated suppression comparable to A151 at a similar dose, but did not 
prove to be as potent as C151 (Fig 2.3e,f).   
 
A151 blocks AIM2 inflammasome activation in response to cytosolic dsDNA. 
 We next investigated the inhibitory potential of the sup ODN A151 on activation of 
the inflammasome.  BMDC were first stimulated with LPS to drive high levels of pro-IL-
1β and pro-IL-18 expression.  Cells were then treated with A151 for one hour before 
exposure to a panel of inflammasome ligands.  Pre-treatment with A151 had no effect on 
IL-1β production in response to the NLRP3 ligands silica, nigericin or ATP, whereas the 
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response to the AIM2 ligand poly(dA:dT) was significantly reduced (Fig. 2.4a).  T his 
pattern of AIM2-specific inhibition was also observed in BMDM and the human THP1 
monocytic cell line (Fig. 2.4b, c respectively).  A151 also suppressed IL-18 secretion in 
response to poly(dA:dT), but not nigericin in BMDC (Fig. 2.4d).  Western blot analyses 
confirmed the reduction of cleaved IL-1β in the supernatants of A151-treated BMDC 
challenged with poly(dA:dT) (Fig. 2.4e).  Furthermore, these blots revealed a decrease in 
caspase-1 cleavage.  T he reduced levels of the active caspase-1 p10 and p20 s ubunits 
following A151 treatment suggests dampened caspase-1 activity.  Importantly, exposure 
to A151 did not diminish levels of pro-IL-1β and pro-caspase-1 in cellular lysates, 
suggesting A151 treatment blocked the activity of the AIM2 inflammasome rather than 
affecting expression of the caspase-1 or its substrate.  S ecretion of the alarmin high 
mobility group box 1 (HMGB1) also requires caspase-1 activation (191, 192) and, much 
like IL-1β and IL-18, HMGB1 release into the supernatant was suppressed by A151 (Fig. 
2.4e).  In contrast to A151, treatment with C151 led to a more modest reduction in IL-1β 
and IL-18.  At 3µM, C151 occasionally reached statistical significance, however its 
inhibitory effect was difficult to visualize by western blot (Fig. 2.4e,f).   
 
Both sequence and backbone composition effect inhibition of AIM2 inflammasome 
signaling. 
 To determine the inhibitory kinetics of A151 and C151 on AIM2 signaling a 
titration experiment was conducted.  BMDC were pre-treated with increasing 
concentrations of A151 and C151 followed by transfection with poly(dA:dT) and 
subsequent IL-1β and IL-18 secretion was measured by ELISA.  This experiment  
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Figure 2.4: A l SI pre\'ents AIM21nflammsome acti\'ntlon In n spon.se to cytosolic dsDNA A, 
BtviDCs or B. BtviDT\•Is were primed with LPS (200 ng/ml; LPS pl'ime alone is control) and chal-
lenged with silic.a (500 ..,.glml). nigeriein ( I 0 }LM). ATP (5 mM) Ol' 300 ng of poly(dA:dT) c.om-
plexed with lipofoc.ramine. 2000 (untreated). Cells were pretreated with A 151 or Cl 51 (3 ~un) as 
indicated and Il- l p secretion into the Sllpernatant was me.asmed by ELISA. C, Tl IP Is were 
difltrent iated overnight with PMA (0.5 ~M). treated a.o; descl'ibed above and IL-l~ wa.o; measured 
by ELISA. D, BMDCs were treated as described and I L-IS wa.o; measured by ELISA. E. lmnm-
noblouing of Il- l p, c.aspase- 1 and I JMGB I in the supernatant.; and lys.ates from BMDCs. F. 
BtviDC we•·e tre.ate.d as above and Il- l p secretion into the Sllpernatant was analyze.d by ELISA. 
Data are. presente.d as mean rL SO f•·o•n three biological replicates repre~o;e.ntative of three e:<peri-
ments. • p < 0.01, •• p<O.OOI. ••• p<O.OOO I 
 63 
revealed that both A151 and C151 were capable of inhibiting AIM2 inflammasome 
activation (Fig. 2.5a,b).  Interestingly, A151 with a half-maximal effective concentration 
(EC50) of 0.360µm was approximately 20 t imes more potent than C151 (EC50 = 
6.16µm).  To determine whether the PS backbone affected A151-mediated inhibition, this 
sup ODN was synthesized with a phosphodiester backbone A151(PD) and tested in 
BMDC and BMDM.  P retreatment with A151(PD) had no significant effect on IL-1β 
release following poly(dA:dT) challenge in either line (Fig. 2.5c,d).  As we had observed 
for IFN-inducing pathways, a PS backbone was essential for inhibition of AIM2 
signaling.  However, whereas C151 was a more potent inhibitor of the IFN-β response, 
A151 proved to more potently suppress AIM2 signaling.  
 Until now we had only tested constructs previously shown to have inhibitory 
properties.  To explore whether the increased inhibitory potency of A151 was due to its 
specific sequence, or a more general property of guanosine rich PS ODNs, we tested the 
inhibitory potential of one class A and two class B stimulatory CpG ODNs.  The class A 
ODN 2336 has a backbone composed of PS linkages on e ither end and 11 interior PD 
bonds.  The two class B ODN, 1826 and 10104, are composed entirely of PS linkages.  
These ODN contain CpG motifs and, when used alone, activate TLR9 leading to DC 
maturation and the secretion of cytokines (11, 193).  However, much like A151, pre-
treatment with 1826 a nd 10104 inhibited IL-1β secretion by BMDC following 
poly(dA:dT) challenge.  By comparison, the partial PS construct, 2336 had no inhibitory 
effect, despite having a similar guanosine content to A151 (Fig. 2.5e).  These findings 
underscored the importance of the PS backbone in AIM2 inhibition and revealed a 
correlation between total guanosine content and potency in PS constructs. 
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Figure 2.5: Sequence and backbone composition afftct suppression of AIM2-mtdiated cyto-
kJne production BMDCs were. prime.d with LPS (200 ng/ml) and challe-nged with 300 ng of 
poly(dA:dT) c.omple:<ed with lipofectamine 2000 (untreated). Cells were prdJ't:ated with an 
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A151 prevents AIM2 inflammasome mediated pyroptosis. 
 In addition to cytokine processing, AIM2 activation leads to a form of programmed 
cell death known as pyroptosis (16, 194).  Pyroptosis is distinct from apoptosis, in that it 
is caspase-1-dependent, leads to rapid plasma-membrane rupture and the release of pro-
inflammatory cytokines; making this form of cell death inherently inflammatory.  Using a 
luminescent cell viability assay, we quantified the survival of BMDC and BMDM 
following poly(dA:dT) challenge.  After 16 hour s of exposure, we observed 70% cell 
death in BMDC and 93% in BMDM.  Similarly to its affects on IL-1β and IL-18 
secretion, A151 potently inhibited pyroptotic cell death in both macrophages and 
dendritic cells (Fig. 2.6a,b).  In BMDM, A151 was able to restore nearly 100% viability 
at dose of 1 µM though it was less effective in BMDC.  Interestingly, C151 had no effect 
in BMDC, but was able to inhibit cell death in BMDM, though at a reduced potency and 
efficacy compared to A151.  In keeping with its effects on c ytokine production 
suppression of pyroptotic cell death was dependent on the PS backbone in both lines (Fig. 
2.6c,d). 
 
A151 prevents IL-1β cleavage in AIM2-reconstituted HEK293T cells.  
 The human HEK293T cell line has proven to be a useful tool for studying 
inflammasome activation.  T ransient transfection of plasmids encoding Aim2, Asc, 
caspase-1 and pro-IL-1β leads to the formation of a functional AIM2 inflammasome 
complex and subsequent IL-1β cleavage (16).  Moreover HEK293T are devoid of 
endogenous TLR expression, allowing us to examine the effects of A151 in a system free 
of TLR signaling (195).  Exposure of AIM2-reconstituted HEK293T cells to 1 µM A151  
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drastically reduced IL-1β cleavage while C151 had no e ffect (Fig. 2.7a).  S uppression 
was not observed when IL-1β cleavage was driven by caspase-1 overexpression alone, 
indicating that A151 inhibits inflammasome activation at a step prior to caspase-1 
activation.  To determine whether the potency of inhibition in this reconstitution assay 
were similar to our primary lines, a dose response experiment was performed.  This 
experiment corroborated our previous findings, demonstrating that while both constructs 
could mediate inhibition at higher doses, A151 was more potent compared to C151 (Fig. 
2.7b).    
 
A151 blocks AIM2 activation in BMDC challenged with MCMV and Listeria. 
 Our lab has previously shown that AIM2 is essential for inflammasome activation 
in response to the viral pathogen MCMV (16).  Secretion of IL-1β by BMDC challenged 
with MCMV was markedly reduced by A151 pretreatment (Fig. 2.8a).  A  number of 
inflammasome receptors including NLRP3, NLRC4 and AIM2 have been implicated in 
the IL-1β response to L. monocytogenes (16, 95, 102, 196, 197).  A151 treatment reduced 
IL-1β production in BMDC responding to L. monocytogenes, a reduction proportional to 
that observed in AIM2-deficient cells (Fig. 2.8b) (16).  C ollectively, these findings 
suggest that A151 blocks AIM2-mediated inflammasome signaling in response to the 
pure dsDNA ligand poly(dA:dT) as well as pathogens such as MCMV and L. 
monocytogenes.  
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A151 prevents ASC dimerization. 
 We next wanted to understand the molecular basis for the suppressive effect of 
A151 on AIM2 inflammasome activation. We therefore examined the ability of A151 to 
modulate AIM2-ASC inflammasome complex assembly. To do s o BMDM were 
challenged with poly(dA:dT) and whole cell lysates were cross-linked and fractionated 
by sequential centrifugation.  F ollowing exposure to poly(dA:dT), we observed an 
increase in the presence of ASC dimers in the macromolecular pellet; a finding consistent 
with inflammasome activation (Figure 2.9a) (101).  P retreatment with A151 reduced 
ASC dimer formation to levels observed in media controls whereas C151 led to a modest 
decrease and A151-PD had no effect.  Consistent with these observations, A151-treated 
cells retained ASC in its soluble, monomeric form, suggesting that A151 blocks 
recruitment of ASC to AIM2, preventing inflammasome assembly.  
 
A151 blocks inflammasome assembly in an AIM2-citrine reporter cell line. 
 A defining feature of inflammasome signaling is the formation of a large, 
multiprotein complex in the cytosol composed of an NLR or ALR sensor, ASC, and 
caspase-1.  This complex can be as large as 2 µm in size and offers a unique opportunity 
to analyze signaling by tracking the localization of inflammasome components in living 
cells (194).  T o visualize the formation of the AIM2 inflammasome, we employed an 
immortalized murine macrophage cell line stably expressing AIM2-citrine and monitored 
inflammasome assembly in live cells.  In resting macrophages, the AIM2-citrine fusion 
protein was diffusely cytoplasmic.  However, stimulation with poly(dA:dT) caused nearly 
50% of these cells to form fluorescent punctate structures or ‘specks’ indicative of AIM2 
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inflammasome formation (Figure 2.9b).  Pre-treatment with A151 strongly inhibited the 
formation of AIM2-citrine specks in our poly(dA:dT)-treated reporter line.  Instead, the 
AIM2-citirine protein remained dispersed throughout the cytoplasm.  In keeping with 
previous data, C151 demonstrated a more modest inhibitory effect only partially 
preventing speck formation.  A similar pattern of inhibition was observed using 
macrophages expressing an ASC-citrine construct (Figure 2.9c).   T hese results are 
consistent with our cytokine data and suggest that A151 mediates inhibition by blocking 
the ability of AIM2 to engage downstream signaling components necessary for 
aggregation. 
 
A151 binds to AIM2.  
A151 has been shown to exert its suppressive effects by association with signal 
transduction molecules such as STAT1 and STAT4 (149, 153).  AIM2 binds stimulatory 
dsDNA via its C-terminal HIN200 domain thus releasing it from a resting, autoinhibited 
conformation and allowing inflammasome formation (73).  To determine whether our sup 
ODN can interact with endogenous AIM2, immortalized murine macrophages were 
treated with with biotinylated A151 or biotiylated C151 for one hour, lysed and incubated 
with streptavidin beads.  These pull-down studies revealed that A151, and to a far less 
extent, C151 were capable of interacting with AIM2. (Fig. 2.10a)  A second pull down 
with biotinylated A151 was performed in the presence of an increasing concentration of 
poly(dA:dT).  The inclusion of poly(dA:dT) during the binding step led to a proportional 
decrease in AIM2 recovery, suggesting A151 competes with poly(dA:dT) for AIM2 (Fig 
2.10b).  
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A151 and C151 bind to IFI16.  
A number of receptors have been implicated in IFN-β induction in response to 
HSV-1 infection, including IFI16, DAI, DHX9, DHX36, RNA Pol III, DDX41 and the 
newly discovered cGAS.  The association of AIM2 with A151 suggests other members of 
the PYHIN family may also associate with A151.  Unterholzner et al. have previously 
demonstrated that IFN-β induction and NF-κB activation in response to cytosolic DNA 
and HSV-1 infection is dependent on the PYHIN protein IFI16 (70).  IFI16 is 
alternatively spliced into three isoforms that differ in the length of the linker region 
between HIN200A and HIN200B.  Using biotinylated A151 and C151 we were able to 
pull down IFI16 from THP1 lysates (Fig. 2.10c).  Interestingly, while A151 associated 
with a larger, approximately 95kDa isoform of IFI16, C151 interacted more strongly with 
the smaller 85kDa isoform.   
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Discussion 
  
Numerous studies have examined the inhibition of TLR9 activation by sup ODN.  
However, until now no s tudies have explored the effects of sup ODN on c ytosolic 
sensing pathways.  This work identifies DNA species capable of broadly inhibiting 
cytosolic dsDNA responses and explores the role of DNA backbone chemistry and 
sequence in mediating suppression.  Our data show that A151 added to the media of 
primary murine dendritic cells and macrophages prevents DNA induced IRF3- and NF-
κB-dependent gene induction in response to cytosolic dsDNA as well as infection with 
HSV-1 and MCMV.  As described previously, A151 did not inhibit LPS-driven cytokine 
production (153), nor did it affect IFN-β induction by Sendai virus, a member of the 
paramyxovirus subfamily that activates the RIG-I pathway.  Notably, Nanostring analysis 
revealed A151 treatment had little effect on the expression profile of resting cells nor did 
it increase expression of anti-inflammatory mediators following stimulation. This 
suggests that it does not induce an anti-inflammatory state but rather blocks activation of 
dsDNA sensing pathways (Fig. 2.11).  
A151 proved to be effective inhibitor of AIM2 inflammasome signaling as well.  
Treatment with A151 prevented AIM2-mediated caspase-1 activation, IL-1β, IL-18 and 
HMGB1 secretion and pyroptotic cell death in response to dsDNA challenge.  Previously, 
Sato et al. uncovered a role for A151 in the inhibition of silica-induced inflammation 
(152).  However, A151 had no effect on secretion of IL-1β or IL-18 in response to the 
NLRP3 ligands silica, nigericin, or ATP.  Silica treatment leads to significant host cell 
death in vitro and we theorize that the inhibitory effects observed in vivo were due to 
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A151’s effect on c ytosolic sensing of host DNA released from dead and dying cells, 
rather than a direct effect on NLRP3 activation.  In addition to A151’s effects on AIM2 
activation by poly(dA:dT), it inhibited IL-1β cleavage in BMDC challenged with the 
viral pathogen MCMV, which has been shown to be entirely dependent on AIM2 (16).  
Moreover, A151 partially blocked the response to the bacterial pathogen L. 
monocytogenes.   
Dose-response experiments gave insight into the kinetics of inhibition and the role 
of sequence and backbone composition.  Multiple studies by Pisetsky and collaborators 
using single base ODN constructs have demonstrated that nucleotide composition affects 
TLR9 suppression (140, 141, 198).  Studies of A151 have found that its guanine residues 
are crucial for inhibition of TLR9, STAT1 and STAT4 signaling (149, 153, 154) .  
Despite this, the role of sequence in A151-mediated inhibition is controversial.  W e 
believe that sequence-specific effects are often lost or minimized at higher 
concentrations, which has led to the misinterpretation that sequence is unimportant.  For 
example, Trieu et al. reported TLR9 responses were inhibited by long ODN with PO 
backbones independent of sequence however they demonstrated differences in construct 
potency at concentrations below 1 µM (127).  
Our experiments revealed that both A151 and C151 inhibit IFN-inducing 
pathways and AIM2 activation at higher concentrations.  However, treatment of cells 
with lower concentrations revealed stark differences in construct potency.  A s we 
demonstrated, A151 proved to be 20-times more potent than C151 in blocking AIM2 
activation in BMDC.  In contrast, the C151 construct was approximately 10-times more 
potent than A151 at inhibiting IFN-induction in the same line.  Differences in inhibitory 
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kinetics were also observed between BMDM and BMDC cell lines.  Consistent with sup 
ODN effects on T LR9 activation, conversion of either construct to a PD backbone 
completely abolished inhibitory activity (127). 
Mechanistically, A151 prevented ASC dimerization in macrophages and 
decreased the formation of cytoplasmic inflammasome specks in both AIM2- and ASC-
citrine reporter lines (Fig. 2.11).  Interestingly, in pull down experiments, A151 bound to 
AIM2 more readily than C151 suggesting a possible explanation for the observed 
differences in suppressive potency.  In keeping with this theory, C151 pulled down more 
IFI16 than did A151.  In addition, these experiments indicated that a PS backbone was 
essential for the interaction between IFI16 or AIM2 and sup ODN.  Results were similar 
whether biotinylated sup ODN was added to the media or directly to lysates suggesting 
sequence affects affinity rather than cellular uptake.  Moreover, the inclusion of 
increasing amounts of poly(dA:dT) with A151 during the binding step led to a 
proportional decrease in AIM2 recovery indicating an affinity-driven competition with 
this stimulatory ligand.  Finally, in addition to pulling down cytosolic receptors, the 
downstream signaling molecule STING also associates with IFN-activating ODNs, such 
as the AT-rich motif isolated from the Plasmodium falciparum genome (224).  However, 
neither A151 nor C151 pulled down this essential signaling adapter.  Thus, we propose a 
mechanism whereby A151 and C151 compete with stimulatory dsDNA for binding to 
AIM2 and IFI16 but do not promote activation of downstream signaling events.   
Interestingly, Unterholzner et al. observed the inhibitory effects of single-stranded 
phosphorothioate DNA on IFI16 while initially identifying it as an innate immune sensor 
(70).  T hey found that both single-stranded and double-stranded forms of their VACV 
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70mer bound to IFI16 but that the single-stranded form acted as a competitive antagonist, 
inhibiting the dsVACV 70mer from inducing IFN-β.  W e have extended these 
observations to other members of the PYHIN family and begun to explore the effects of 
sequence on inhibitory potency.  Ashman et al. had previously shown the 4348 construct 
to be a significantly more potent TLR9 inhibitor than A151’s ‘TTAGGG’ motif.  
However 4348 and A151 inhibited poly(dA:dT) stimulation of IFN responses comparably 
and both were less potent than C151.  Likewise, the class B stimulatory ODNs and A151 
inhibited AIM2 activation similarly, while the class A stimulatory ODN had no effect.  
This suggests that while a PS backbone is essential for inhibition, total guanine content 
rather than a specific sequence may influence binding kinetics.  Importantly the class B 
stimulatory constructs maintained their ability activate TLR9-mediate signaling.  The 
inhibition observed was specific for AIM2-mediated inflammasome signaling in response 
to stimulation with poly(dA:dT). 
PS modified constructs are quickly taken up by macrophages and dendritic cells 
via both scavenger receptor-mediated endocytosis and pinocytosis (138).  Multiple wash 
steps following A151 or C151 pre-treatment had no e ffect on the construct’s ability to 
inhibit IL-1β production.  T his suggests the transfection of poly(dA:dT) using 
lipofectamine did not influence the uptake of A151 and C151.  Likewise inhibition was 
observed following MCMV or Listeria infection, stimuli that do not require 
lipofectamine transfection.  Importantly, both the PS backbone and high guanosine 
content have been shown to increase construct aggregation.  Aggregation of A151 could 
potentially lead to differences in cellular uptake, localization, and receptor avidity 
compared to C151; which might account for A151’s more potent inhibitory effect on 
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AIM2.  Further studies are needed to determine whether these constructs aggregate and 
how this interaction effects inhibition.  
Recently, a crystal structure of the AIM2 HIN200C domain complexed to double-
stranded DNA was reported (73).  T his study indicated that dsDNA recognition was 
accomplished largely through electrostatic interactions between the HIN domain and the 
DNA’s sugar-phosphate backbone and was therefore independent of sequence.  One 
explanation for the sequence dependence of single-stranded sup ODN is that a single-
stranded DNA species may theoretically allow HIN200 residues greater access to its 
nucleotide bases than a double-stranded construct.  Indeed, the interaction between 
dsDNA and AIM2 was reported to be highly flexible, allowing tilting and sliding (73).  In 
addition to improved access of ssDNA, this inherent flexibility may allow additional 
residues to participate in the binding of ssDNA.  Thus, while data suggests the PS 
backbone of sup ODN is essential for a strong interaction with members of the PYHIN 
family it is tempting to speculate that nucleotide residues affect minor contributions to 
the association thereby influencing relative affinity.   In addition to describing the 
residues responsible for dsDNA binding, docking studies indicate that AIM2’s PYD 
domain interacts with its HIN200 domain leading to autoinhibition at rest (73).  T his 
interaction is released upon binding of dsDNA to the HIN domain, freeing the PYD 
domain to recruit ASC.  Studies defining the residues responsible for the interaction of 
A151 and AIM2 and how the interaction effects AIM2’s conformation will help elucidate 
the mechanism by which A151 associates with, but does not activate AIM2, while 
dsDNA both associates and activates.  
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Alternative splicing of the spacer region between IFI16’s HIN200 domains leads 
to the production of three isoforms (74).  Interestingly, we found that A151 and C151 
associated with different isoforms of IFI16.  The functional significance of these isoforms 
remains unknown, however, it is conceivable that differences observed in inhibitory 
potency are the result of the selective interaction of A151 and C151 with different IFI16 
isoforms.  Further analysis, for example mass spectrometry of pulled down proteins, is 
needed confirm the specificity of this interaction.  
Administration of A151 has been used in murine models of shock, lupus, 
inflammatory arthritis, and atherosclerosis.  A growing body of evidence suggests 
cytoplasmic DNA sensing contributes to the pathogenesis of many of these same 
diseases.  T he identification of A151 as an inhibitor of the AIM2 and IFI16 signaling 
pathways adds to our understanding of how this sup ODN modulates the immune 
response.  We theorize that the interaction of sup ODN with members of the PYHIN 
family may explain the robust and global anti-inflammatory effects observed in these 
disease models.  These observations invite further investigation into the potential effects 
of sup ODN on ot her members of the PYHIN family as well as other cytosolic DNA 
sensors.   
 
 
 
 
 
 
 
 
 
 
 
 
 81 
 
 
 
 
 
CYTOSOL 
dsONA 
~ 
A151 
--
NUCLEUS 
e • 8C"IIve ll·1fl 
•• 
~·" 'J ..
AIM2 
~ AIM2 
( ::--=s "- ~151 
IFI16 ---- ~----~---
AIM2 
00 IFN~gene 
~
IFI16 
~ 
MITOCHONDRION 
figurt> 2.11: Sch.-mati<' model uf A I 5 I and C I 5 1-mc:diatl'd inhibition uf cytuplumic rt><'f'pton AJM2 
binds to dsDNA vin its HfN200 domain which induces a conformational change. AfM2's PYD domain 
recruits ASC which in hlrn rccruits pro-caspase·l. This c lose assoc.iation ofpro-ca.<ipase-1 molecules 
enables self-cleavage into active rospase-1. Active-caspase-1 in tum cleaves pro-l~IP and pro-Il lS into 
their active fumlS. The A 151 construct bound to AIM2 but prevmted recruitment of the downstream 
adaptor molecule ASC and subsequent inRammasome complex assembly. [f l l6 binds to dsDNA and 
signals via SiiNG which activates 1"BKI leading to the phosphorylation of IRF3. Phosphorylatod IRF3 
translocates to the nucleus and activates transcription of Type I JF'N and JSG. The CIS I construct bound to 
IF J16 but prevented recruitment of STING and subscquent lf'N induction 
 82 
Preface to Chapter III 
 
The chapters of this dissertation have appeared in the following publications/manuscripts: 
 
John J. Kaminski, Stefan A. Schattgen, David M. Knipe and Katherine A. Fitzgerald. 
2013. Cell type-specific activation of the NLRP3 and NLRP12 inflammasomes in 
response to HSV-1. Unsubmitted. 
 
John Kaminski performed all experiments, Stefan Schattgen contributed to Fig 3.1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 83 
Chapter III 
 
Cell type-specific activation of the NLRP3 and NLRP12 inflammasomes 
in response to HSV-1  
 
Abstract 
  
The innate immune system responds to HSV-1 infection by producing an array of 
cytokines, chemokines and type I interferons critical for controlling viral replication and 
coordinating an adaptive response.  The cytokines IL-1β and IL-18 are important effector 
molecules in the innate response to HSV-1 in vivo.  H owever, the pattern recognition 
receptors responsible for the production and maturation of these cytokines have not been 
fully defined.  We show here that HSV-1 induces IL-1β transcription in dendritic cells 
and macrophages in a TLR2-MyD88-dependent manner.  Following translation, IL-1β 
and IL-18 exist as inactive precursors that must be proteolytically cleaved by a 
multiprotein complex known as the ‘inflammasome’ to yield their active forms.  
Currently six receptors, NLRP1, NLRP3, NLRC4 (IPAF), NLRP12, AIM2 and IFI16 
have been reported to assemble inflammasomes.  In the present study, we found that the 
NLRP3 inflammasome is responsible for maturation of IL-1β in macrophages and 
dendritic cells in response to HSV-1 while NLRP12 regulates IL-1β production in 
neutrophils.   
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Introduction 
 
Herpes simplex virus 1 (HSV-1) is a common and highly contagious viral 
infection that affects populations worldwide (199).  The early innate immune response to 
HSV-1 infection is essential for controlling HSV-1 viral load and triggering an effective 
adaptive immune response (200).  Innate immune cells detect infection through several 
classes of pattern recognition receptors (PRRs).  A large number of PRRs have been 
implicated in the response to HSV-1 including TLR2, TLR3, TLR9, RIG-I, MDA-5, 
DAI, IFI16, DDX41, cGAS and NLRP3.  Upon activation, these receptors initiate signal 
cascades that lead to the production of cytokines, chemokines and Type I interferons - 
effector molecules that recruit and activate leukocytes and establish an antiviral 
environment.  Recent studies have identified IL-1β and IL-18 as key mediators of 
resistance to HSV-1 infection.  Mice genetically deficient in IL-1β are unable to mount 
robust immune responses to HSV-1 infection which leads to viral dissemination and 
lethal encephalitis (177).  IL-18 treatment has also been shown to reduce viral titers and 
increase survival in HSV-1 challenged mice (201).  Moreover IL-18-deficient mice are 
more susceptible to lethal encephalitis likely due to an impaired NK cell response.  
Despite the importance of IL-1β and IL-18 in the response to HSV-1 infection, the PRRs 
and downstream signal pathways responsible for the production of these cytokines 
remain poorly defined. 
 IL-1β and IL-18 are secreted via an unconventional mechanism that differs from 
the classical vesicle-mediated pathway employed by many other effector molecules such 
as TNF-α (202).  This nonclassical pathway involves the coordinated action of two PRR.  
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The first drives NF-κB-dependent transcription and translation of pro-IL-1β and pro-IL-
18.  Following synthesis, these immature interleukins, which lack leader sequences, are 
maintained in the cytosol (203).  A second signal is then required to mediate assembly of 
a multi-protein complex termed the inflammasome (204).  The inflammasome provides a 
platform for the activation of the zymogen caspase-1, an enzyme that, in its active form, 
cleaves pro-IL-1β and pro-IL-18 into mature cytokines (205, 206).  Activation of 
inflammasome receptors results in either direct engagement of caspase-1 or recruitment 
through the adapter molecule apoptotic speck protein with CARD domain (ASC) that in 
turn recruits caspase-1.  Thus, four members of the nucleotide-binding domain leucine-
rich repeat (NLR) superfamily have been shown to assemble inflammasomes.  T hese 
include NACHT, LRR and PYD domain-containing proteins 1, 3 and 12 (NLRP1, 
NLRP3 and NLRP12) and NACHT, LRR and CARD domain-containing protein 4 
(NLRC4 or IPAF) (15, 95, 98-100, 110-117).  NLRP3, the prototypical NLR, is primarily 
known to respond to crystalline/particulate substances such as silica, alum, asbestos and 
β-amyloid protein, but has recently been shown to be important in detecting influenza 
and adenovirus (100, 104).  By comparison the precise function of NLRP12 remains 
controversial.  Studies have ascribed seemingly conflicting roles to NLRP12 in the 
inflammatory response. Wang et al. found that NLRP12 can activate the transcription 
factor NF-κB and caspase-1-mediated IL-1β processing, thus acting in a pro-
inflammatory capacity.  Elsewhere, NLRP12 is described as antagonizing noncanonical 
NF-κB activity as well as TLR and TNFR signaling (120).  NLRP12 is expressed at high 
basal levels in granulocytes (118).  Recently NLRP12 was shown to assemble an 
inflammasome in response to Yersinia pestis (117).  
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In addition to members of the NLR family, our lab and others have recently 
reported the ability of the PYHIN protein absent in melanoma-2 (AIM2) to produce an 
inflammasome in response to bacterial and viral double-stranded DNA (16, 17).  AIM2 
dependent IL-18 secretion was found to be critical for controlling MCMV replication in 
mice through the activation of NK cell-dependent IFN-γ production.  Another member of 
the PYHIN family, interferon gamma-inducible protein 16, (IFI16) has recently been 
shown to assemble an inflammasome in response to KSHV infection (82).  Interestingly, 
while other inflammasome assembling receptors are localized to the cytosol, IFI16 is 
thought to bind stimulatory DNA in the nucleus and then relocate to the perinuclear 
region before assembling an inflammasome structure.  However, this function remains 
controversial as other studies have found IFI16 heterdimerizes with NLRP3 and AIM2 to 
suppresses activation of the inflammasome (207).  Thus the precise role of IFI16 remains 
to be determined.   
As with many viruses, HSV-1 has evolved a number of strategies to evade the 
host innate immune response.  Viral proteins such as ICP27 inhibit Type I IFN signaling 
while ICP34.5 stimulates dephosphorylation of eIF2α relieving PKR-mediated 
translational block (208, 209).  One such anti-inflammatory protein, ICP0, an immediate-
early HSV-1 gene, is a member of the RING finger family of proteins.  It is responsible 
for transactivation of viral genes through ubiquitination of cellular proteins thereby 
targeting them for degradation (210).  In this manner, it reduces the cell’s antiviral 
response by dissolving nuclear promyelocytic leukemia protein (PML) bodies, degrading 
MyD88, and inhibiting the transcription factors IRF3 and IRF7 (169).  While the wild-
type KOS strain of HSV-1 was a poor inducer of pro-IL-1β, the 7134 strain of HSV-1, 
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deficient in Infected Cell Polypeptide 0 (ICP0) strongly induced expression.  In order to 
visualize pro-IL-1β expression and maturation, we utilized this 7134 strain.   
In the present study, Nanostring technology was used to characterize the basal 
expression levels of a panel of cytokines, chemokines and innate immune receptors in 
BMDC.  The same panel was then used to examine mRNA induction in wild-type, 
STING- and MyD88-deficient cells following HSV-1 challenge.  This analysis revealed 
that the MyD88 adapter was required for pro-IL-1β induction following HSV-1 
challenge.  In contrast IL-18 induction required contributions from both MyD88- and 
STING-mediated signaling.  Using TLR2- and TLR9-deficient cells, we found the TLR2-
MyD88 pathway was necessary for pro-IL-1β induction.  W e go on t o show that the 
NLRP3 inflammasome is required for IL-1β production in macrophages and dendritic 
cells.  In contrast, we found that neutrophils relied on t he related NLRP12 protein to 
secrete mature IL-1β in response to HSV-1.  
 
Results 
 
Characterization of the innate immune response to HSV-1 in dendritic cells 
TLR2, TLR3 and TLR9 have all been implicated in the innate response to HSV-1.  
Additionally, a growing list of cytoplasmic receptors, have been shown to mediate 
cytokine and Type I IFN production.  Evidence suggests that certain receptors, such as 
TLR9, may be important for pro-inflammatory responses in specific cell subtypes such as 
plasmacytoid dendritic cells while TLR2 and various cytoplasmic receptors play a 
significant role in conventional dendritic cells and macrophages (178, 211).  To define 
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the relative contributions of these receptors to the inflammatory response, we harvested 
bone marrow from wild-type and mice deficient in MyD88 and STING, two crucial 
signaling components downstream of TLRs and cytosolic receptors.  Using BMDC, we 
compared the mRNA levels of a panel of Type I IFN, cytokines, chemokines, and PRRs 
before and after HSV-1 infection by multiplex gene expression analysis using nCounter 
(Nanostring) technology (Fig. 3.1).  As we had observed previously, resting BMDC 
expressed particularly high mRNA levels of TLR2 and TLR4.  Other receptors such as 
TLR1, TLR9, TLR3, MDA-5, NLRP3, AIM2 and IFI16 were expressed at lower levels 
basally but were induced following HSV-1 infection (Fig. 3.1 and Table 3.1).  Studies 
have found that TLR signaling not only primes, but also ‘licenses’ the inflammasome by 
enhancing expression of inflammasome assembling receptors such as NLRP3 (91).  
Indeed, NLRP3 expression was increased nearly 20-fold by HSV-1 challenge and this 
induction was MyD88-dependent.  Interestingly, our analysis revealed important 
differences in the contributions of MyD88 and STING signal pathways to Type I IFN and 
cytokine responses.  In wild-type BMDC, IFN-β and IFN-α were strongly induced by 
HSV-1 infection.  However, this Type I IFN response was completely lost in STING-
deficient cells, while MyD88 deficiency had no effect (Fig 3.1 and Table 3.2).  Not 
surprisingly, STING-deficient cells also demonstrated impaired induction of various IFN-
stimulated genes including IFI204, IFI205, AIM2, LGP2, MDA-5, RIG-I, IRF7, TREX1 
and viperin.  Interestingly, STING was also important for the induction of caspase-1, 
NLRP12 and NLRP6 following HSV-1 infection.  In contrast, MyD88 proved to be more 
important for the induction of cytokines including TNF-α, pro-IL-1β, IL-1α and the IL- 
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Table 3.1 : Nanostring Normalized mRNA Counts  
   Stimulation   
   Media     HSV   
Gene C57Bl/6 STING-/- MyD88-/- C57Bl/6 STING-/- MyD88-/- 
       
Cyokines, chemokines and their receptors    
Ifna4 1 10 11 101 10 109 
Ifnb1 4 2 4 1390 3 830 
Il-1a 11 7 10 2541 1459 69 
Il-1b 22 28 5 8697 5458 27 
Il1ra 71 51 32 38844 904 4305 
Il6 4 13 8 5981 705 341 
Il-10 247 227 271 3221 406 507 
Il12a 3 3 7 164 46 112 
Il12b 1 6 2 700 930 25 
Il-18 163 104 107 2045 126 976 
Il21 8 6 1 59 3 40 
Il23a 1 1 1 14 6 8 
cxcl1 9 9 2 288 5330 28 
cxcl10 46 22 17 117437 804 84494 
tnfa 104 103 30 12913 12145 3004 
       
PRRs, downstream signaling components    
aim2 175 141 137 1319 106 1161 
Ifi204 254 92 129 17878 437 11149 
Ifi205 14 4 6 33916 374 12545 
Irf7 175 35 164 16182 154 9994 
lgp2 145 133 172 7205 226 4898 
mda5 335 252 244 24102 485 13827 
mnda 226 67 105 19925 922 11583 
nlrc4 115 176 38 119 204 146 
nlrc5 126 125 103 2766 123 2001 
nlrp12 3 6 7 40 7 21 
nlrp3 320 310 220 5561 5342 1282 
nlrp6 1 15 8 51 4 24 
rig-i 64 18 56 67293 2119 18620 
tlr1 127 89 60 744 540 93 
tlr11 9 8 5 59 7 42 
tlr2 1349 1212 441 3918 5242 3953 
tlr3 118 86 89 3794 47 2949 
tlr4 1510 1499 1199 1446 542 1492 
tlr5 3 9 4 125 11 78 
tlr7 863 796 724 1469 408 1332 
tlr8 2497 2535 1976 3779 781 2439 
tlr9 286 225 238 1469 99 1176 
casp1 632 532 440 8608 1061 4127 
viperin 106 33 78 218056 710 153290 
zbp1 52 20 29 8052 53 5879 
       
Transcription factors      
stat1 411 346 323 8568 632 7554 
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   Media     HSV   
 C57Bl/6 STING-/- MyD88-/- C57Bl/6 STING-/- MyD88-/- 
       
Proinflammatory enzymes     
cox2 7 21 5 8763 1396 91 
trex1 612 503 407 11055 1383 6069 
nos2 11 7 5 5164 31 396 
       
Anti-inflammatory signaling components    
socs1 8 11 12 7215 543 3790 
duba 469 493 359 1772 781 1201 
a20 159 157 69 8020 2384 1159 
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Table 3.2 : Nanostring mRNA Fold Induction Compared to Media 
      
   HSV infected / Media     
Gene C567Bl/6 STING-/- MyD88-/-   
cxcl10 2546.7 36.2 4979.7   
Ifi205 2500.7 101.1 2033.2   
viperin 2061.2 21.3 1967.8   
Il6 1469.9 54.5 40.2   
cox2 1292.3 65.7 16.9   
rig-i 1055.7 114.6 335.3   
socs1 886.7 49.0 307.1   
Il12b 700.3 167.6 16.2   
Il1ra 550.8 17.8 132.9   
nos2 475.9 4.2 85.7   
Il-1b 400.8 196.7 5.9   
Ifnb1 341.6 1.5 215.2   
Il-1a 234.2 197.2 6.9   
zbp1 156.2 2.6 200.6   
tnfa 123.6 118.3 99.9   
Irf7 92.5 4.4 60.8   
mnda 88.0 13.8 110.4   
Ifna4 74.3 1.0 10.1   
mda5 71.9 1.9 56.6   
Ifi204 70.5 4.8 86.6   
Il12a 60.5 16.7 16.1   
a20 50.5 15.2 16.7   
lgp2 49.6 1.7 28.5   
tlr5 46.3 1.2 20.3   
nlrp6 37.7 0.2 2.8   
tlr3 32.2 0.5 33.2   
cxcl1 30.4 576.4 18.5   
nlrc5 21.9 1.0 19.4   
stat1 20.8 1.8 23.4   
trex1 18.1 2.7 14.9   
nlrp3 17.4 17.2 5.8   
nlrp12 14.9 1.1 3.1   
Il23a 13.9 6.4 10.8   
casp1 13.6 2.0 9.4   
Il-10 13.0 1.8 1.9   
Il-18 12.6 1.2 9.1   
aim2 7.5 0.8 8.5   
Il21 7.2 0.5 52.3   
tlr11 6.2 0.9 9.0   
tlr1 5.8 6.1 1.5   
tlr9 5.1 0.4 5.0   
duba 3.8 1.6 3.3   
tlr2 2.9 4.3 9.0   
tlr7 1.7 0.5 1.8   
tlr8 1.5 0.3 1.2   
nlrc4 1.0 1.2 3.9   
tlr4 1.0 0.4 1.2   
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12 p40 s ubunit (IL-12B) (Fig. 3.1 and Table 3.2).  In addition, maximal induction of 
cytokines such as IL-6, pro-IL-18 and IL-10 required both signal pathways to be intact.  
Thus, HSV-1 infection activates both TLR-MyD88 and cytosolic receptor-STING 
pathways that function both independently and synergistically. 
 
HSV-1 induces transcription of pro-IL-1β in a TLR2-MyD88-dependent manner  
Having broadly defined the inflammatory pathways activated by HSV-1, we 
focused our investigation on t he mechanism of pro-IL-1β induction.  We began by 
comparing the ability of the wild-type KOS HSV-1 strain and the 7134 s train to drive 
pro-IL-1β transcription.  In keeping with ICP0’s role as an inhibitor of the inflammatory 
response, the wild-type KOS strain induced very little pro-IL-1β while infection with the 
ICP0 knockout strain, 7134 led to a 200-fold increase in pro-IL-1β mRNA in BMDM 
(Fig. 3.2a).  Treatment of the 7134 strain with UV-irradiation further increased the pro-
IL-1β mRNA levels, indicating that replication was not required for pro-IL-1β 
production.  We next examined the expression of pro-IL-1β in BMDM and BMDC 
deficient in MyD88.  Induction of pro-IL-1β by HSV-1 and LPS was abrogated in 
MyD88 knockout lines (Fig 3.2b,c).  This confirmed our Nanostring analysis, indicating 
that TLR recognition of HSV-1 was responsible for pro-IL-1β induction.  The MyD88 
adapter molecule is important for TLR2 and TLR9 signaling, but unnecessary for TLR3-
driven responses.  T o determine if TLR2 or TLR9 were responsible for pro-IL-1β 
induction, the response of BMDMs and BMDCs derived from TLR2-, TLR9- and 
TLR2/9-deficient mice was examined.  T ranscription of pro-IL-1β was completely 
abrogated in TLR2 and TLR2/9, but not TLR9 knockouts (Fig. 3.2d,e).  Interestingly,  
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augmenting the TLR2-driven response in macrophages.  We also examined TNF-α loss 
of TLR9 in BMDMs led to a partial reduction in IL-1β transcription.  N evertheless, 
induction remained entirely dependent on TLR2, suggesting a limited role for TLR9 in 
expression in TLR2, TLR9 and TLR2/9 knockouts and found that like pro-IL-1β, 
induction was dependent on T LR2 (Fig 3.2f).  These findings demonstrate TLR2’s 
central role in dendritic cell and macrophage-dependent cytokine and chemokine 
responses to HSV-1 (178). Thus the TLR2-MyD88 signaling pathway is necessary for 
HSV-1-driven ‘priming’ of the inflammasome in dendritic cells and macrophages 
through the production of pro-IL-1β and ‘licensing’ via the upregulation of 
inflammasome receptors. 
 
HSV-1 induces IL-1β secretion in PEC, BMDM and BMDC 
Secretion of mature IL-1β depends on both transcription and translation of the 
pro-forms of this cytokine as well as activation via inflammasome signaling.  Although a 
number of studies have demonstrated that IL-1β and IL-18 are important for the anti-viral 
responses in vivo, how HSV-1 activates the inflammasome is not well understood (88, 
177).  An early study found the McIntyre strain of HSV-1 could induce caspase-1 
activation and cleavage of IL-1β in THP-1 cells but failed to implicate a specific receptor 
in inflammasome assembly (100).  A recent report by Johnson et al. suggested HSV-1 
infection induces the transient recruitment of NLRP3 and IFI16 to inflammasome 
complexes (181).  A lthough the authors were able to visualize IL-1β cleavage in the 
cellular lysates following HSV-1 infection they could not detect it in the supernatants and 
suggested that HSV-1 is able to block IL-1β secretion through multiple mechanisms 
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(181).  Other studies using human macrophages have also failed to detect IL-1β secretion 
following HSV-1 challenge (212).  Using an LPS prime prior to HSV-1 challenge enable 
detection of IL-1β secretion into the supernatant (Fig 3.3a,b).  Both the wild-type KOS 
HSV-1 strain and the 7134 strain were able to induce IL-1β secretion, however the 7134 
strain produced approximately twice as much (Fig. 3.3a).  HSV-1 infection, in general, 
did not induce high levels of IL-1β secretion compared to ATP or poly(dA:dT) controls; 
therefore, we chose to use the 7134 s train moving forward in order to compare 
differences in IL-1β production in inflammasome-deficient cell lines.  Levels of IL-1β 
secretion increased as the 7134 HSV MOI was raised (Fig. 3.3b).  In addition, maturation 
of IL-1β was blocked by the chemical caspase-1 inhibitor z-VAD-FMK, suggesting 
secretion was indeed caspase-dependent (Fig 3.3c).    
 
IL-1β maturation is mediated by NLRP3 in dendritic cells and macrophages 
To date, two PRRs have been shown to assemble inflammasomes and mediate IL-
1β and IL-18 cleavage in response to viral infection.  T hese include NLRP3, that has 
been shown to respond to influenza A virus and adenovirus, and AIM2, that responds to 
murine cytomegalovirus and vaccinia virus.  R athinam et al. previously demonstrated 
that AIM2 is not involved in inflammasome assembly in response to HSV-1 (16).  To 
evaluate the contribution of NLRs to inflammasome activation, BMDMs and BMDCs 
derived from NLRP3, NLRP12, ASC and capase-1-deficient mice were primed with LPS 
then challenged with the 7134 s train of HSV-1.  We found that while wild-type 
macrophages and DCs were able to secrete IL-1β in response to HSV-1, those lacking 
NLRP3, ASC and caspase-1 were unable to respond (Figure 3.3d,e).  Importantly,  
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NLRP3-deficient cells were still able to respond normally to poly(dA:dT), a synthetic 
DNA species that activates AIM2 (Fig. 3.3f).  To confirm this finding, protein was 
extracted from the supernatants and IL-1β was visualized by Western blot (Fig. 3.3f,g).  
In keeping with our ELISA results, NLRP3-deficient BMDC demonstrated reduced 
production of mature IL-1β in response to HSV-1.  In contrast, NLRP12-deficient 
BMDCs showed no defect in IL-1β production (Fig. 3.3g).  
 
IL-1β maturation is mediated by NLRP12 in neutrophils 
During early stages of HSV-1 infection, neutrophils infiltrate areas of viral 
replication in large numbers (213).  To examine the role of these PRRs in neutrophils, we 
elicited a neutrophil-enriched peritoneal exudate.  Although neutrophil migration in 
NLRP12-deficient mice was found to be impaired in a murine model of contact 
hypersensitivity (122), no defect in neutrophil recruitment to the peritoneum was 
observed following thioglycollate injection.  Compared to dendritic cells and 
macrophages, neutrophils express high basal levels of NLRP12 that is increased 
following stimulation with HSV-1 (Fig 3.4a).  In contrast to the macrophage and 
dendritic lines tested, neutrophils relied on NLRP12 to secrete IL-1β in response to HSV-
1 (Fig. 3.4b).  Unlike IL-1β, secretion of TNF-α was not reduced by the loss of NRLP12, 
indicating a specific deficit in inflammasome function rather than a general loss of 
responsiveness (Fig. 3.4c).   These results were confirmed by Western blot (Fig. 3.3c).  
The smear observed in the media control, ASC-deficient lane is an artifact not observed 
in subsequent Western blots.  Unlike other cell types tested, thioglycollate-elicited 
neutrophils did not require priming with LPS.  Exposure to HSV-1 alone was sufficient to 
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induce IL-1β secretion.  IL-1β release was also abolished in ASC-deficient mice, 
suggesting that NLRP12 utilizes ASC to assemble an inflammasome (Fig 3.4d) (214). 
 
Discussion 
 
 The cytokines IL-1β and IL-18 play a crucial role in the immune response to 
HSV-1.  Mice genetically deficient in IL-1β fail to mount a robust immune response to 
HSV-1, which leads to increased viral load, dissemination and death (177).  Similarly, 
genetic deficiency in IL-18 increases susceptibility to HSV-1 infection while 
administration of IL-18 is protective (88, 201).  In this study, we characterized the 
receptors and pathways responsible for the induction and maturation of IL-1β and IL-18 
in dendritic cells, macrophages and neutrophils in response to HSV-1.  We began by 
examining the basal expression levels of cytokines, chemokines and PRRs and their 
induction following HSV-1 infection.  The receptors expressed at rest may be of 
particular importance during HSV-1 infection as IL-1β production in vitro has been 
reported to be early and brief, perhaps due to subversion of cellular machinery at later 
time points (181, 215).  We found BMDC expressed high basal levels of TLR2 and 
NLRP3 mRNA, which was further increased following HSV-1 infection.  Dendritic cells 
and macrophages employed the TLR2-MyD88 pathway to drive expression of pro-IL-1β 
following HSV-1 infection.  W hile expression of pro-IL-1β was negligible following 
challenge with the wild-type KOS HSV-1 strain, it was robustly induced by the ICP0-
deficient 7134 strain.  This finding agrees with a previous report demonstrating that ICP0 
inhibits TLR2-mediated inflammatory cytokine production (168).  Interestingly, in 
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contrast to pro-IL-1β, expression of pro-IL-18 was dependent on both MyD88 and 
STING dependent pathways.   
Although a number of studies have failed to detect IL-1β secretion by 
macrophages or fibroblasts infected with HSV-1, we found that with prior LPS 
stimulation, HSV-1 challenge generated sufficient IL-1β production by cultured 
macrophages and DCs to allow detection in cellular supernatants (181, 212).  Moreover, 
secretion was dependent on c aspase activity as it was blocked by the chemical pan-
caspase inhibitor z-VAD-FMK.  Secretion of cleaved IL-1β into supernatant was evident 
by Western blot.  However, the secretion of active caspase-1 subunits was not observed.  
In a recent study, NLRP3 and IFI16 were found to associate with ASC 4 hours after 
HSV-1 infection (181).  However, at later time points, this association was lost.  The 
authors found that HSV-1 induced the degradation of IFI16 in an ICP0-dependent 
manner.  By comparison, NLRP3 was not degraded, but after early time points no longer 
colocalized with caspase-1 (181).  Thus, the authors hypothesized that HSV-1 had 
evolved mechanisms to degrade IFI16 and sequester caspase-1 in actin clusters in order 
to inhibit inflammasome activation.  This may explain why they were unable to detect 
secretion of active IL-1β into the supernatants (181).  Importantly, our LPS priming 
strategy induced high levels of pro-IL-1β expression allowing the visualization of IL-1β 
secretion in the supernatants.  However, sequestration of caspase-1 may account for our 
inability to detect secretion of the active caspase-1 subunits.   
Our findings suggest HSV-1 induces secretion of active IL-1β through activation 
of the NLRP3 inflammasome receptor in dendritic cells and macrophages.  Loss of 
NLRP3, the adapter ASC, or capase-1 led to a reduced IL-1β response.  Notably, 
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NLRP3-deficient BMDC and BMDC still produced small amounts of IL-1β in response 
to HSV-1 perhaps indicating other receptors such as IFI16 may contribute to IL-1β 
production as was suggested by Johnson et al (181).  Whether IFI16 is a bona fide 
inflammasome assembling receptor is still under debate.  E vidence for this function is 
often circumstantial and based on colocalization of IFI16 with ASC, an interaction which 
others have suggested, in fact, interferes with the activity of NLRP3 and AIM2 
inflammasomes (82, 207).  In addition, IFI16 has been shown to be important for Type I 
IFN induction in response to HSV-1 and treatment with IFN strongly augments the 
cytokine response to HSV-1 (70, 216).  T hus IFI16 may potentiate cytokine responses 
indirectly by inducing IFN rather than by direct inflammasome assembly.   
In contrast to dendritic cells and macrophages, IL-1β secretion in neutrophils was 
dependent on NLRP12.  Neutrophils are the first infiltrating leukocytes observed at sites 
of HSV-1 infection.  A lthough neutrophils are historically thought of as anti-bacterial, 
recent evidence suggests they play an important role in the antiviral response (217, 218).  
Vladimer et al. recently reported a role for the NLRP12 inflammasome in recognizing the 
bacterial pathogen Yersinia pestis (117).  In this study, NLRP12 was important for IL-1β 
and IL-18 release from neutrophils and macrophages.  Moreover, the IL-18 produced by 
NLRP12 stimulated IFN-γ production that proved to be essential for limiting Y. Pestis 
infection.  We found NLRP12 mRNA expression was low in resting BMDC, but could be 
induced following HSV-1 stimulation.  H owever, NLRP3 was constitutively expressed 
and, following HSV-1 challenge, induced to levels more than a hundred-fold higher than 
NLRP12.  By comparison we found NLRP12 expression was high basally in neutrophils.  
While both NLRP3 and NLRP12 can be activated by HSV-1, the kinetics of IL-1β 
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secretion are known to be rapid and brief and evidence suggests HSV-1 has mechanisms 
for degrading receptors and sequestering caspase-1 (181).  Thus, inflammasome 
formation may rely heavily on whichever receptor is constitutively expressed at the time 
of HSV-1 infection.  Importantly, the neutrophil-rich peritoneal exudate utilized in these 
experiments did contain small numbers of other inflammatory cells including 
macrophages and B cells.  It is possible these resident and infiltrating inflammatory cells 
contributed to the observed phenotype.  Additional experiments using negative selection 
to further purify the neutrophils are necessary to confirm the specific role of NLRP12 in 
inflammasome formation in neutrophils.   
Previous studies have shown that IL-1β and IL-18 are important in the response to 
HSV-1.  This dissertation demonstrates that the TLR2-MyD88 signaling pathway is 
responsible for IL-1β expression and that MyD88 and STING act cooperatively to induce 
IL-18.  Johnson et al. observed the association of NLRP3 and ASC and the cytoplasmic 
accumulation of cleaved IL-1β following HSV-1 infection.  I showed herein that LPS 
priming of cells prior to HSV-1 challenge results in secretion of mature IL-1β into the 
supernatant.  M oreover, I demonstrated that NLRP3-deficient macrophages and DCs 
secrete significantly lower amounts of IL-1β.  In addition, I have provided evidence that 
NLRP12 is important for IL-1β secretion in neutrophils.  The inhibitory effects of the 
ICP0 protein on IL-1β secretion and our inability to observe caspase-1 secretion into the 
supernatants indicate that HSV-1 has evolved multiple strategies to curtail IL-1β 
production.  These studies provide a methodology for further investigation into 
inflammasome signaling in response to HSV-1, as well as the subversion of this pathway.  
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Chapter IV  Materials and Methods 
 
Reagents and Plasmid Constructs 
ATP, LPS, nigericin and poly(dA:dT) were from Sigma-Aldrich (St. Louis, MO).  
A151 (5’-TTAGGGTTAGGGTTAGGGTTAGGG-3’), C151 (5’-
TTCAAATTCAAATTCAAATTCAAA-3’), 4348 (5’-TCGTATCCTGGAGGGGAAG-
3’), 1826 ( 5’-TCCATGACGTTCCTGACGTT-3’), 10104 (5’-
TCGTCGTTTCGTCGTTTTGTCGTT-3’), 2336 (5’-GGGgacgacgtccgtGGGGGG-3’) 
constructs were synthesized by IDT technologies (Coralville, IA) (219-221).  Residues 
with phosphorothioate linkages are capitalized.  A 3’-biotin tag was added to the sup 
ODN sequence for pulldowns.  mCMV (Smith strain) was a gift from R. Welsh (UMASS 
Medical School, MA), L. monocytogenes (clinical isolate 10403s) was from V. 
Boyartchuk (UMASS Medical School, MA).  HSV-1 (KOS and 7134) was a gift from D. 
Knipe (Harvard Medical School, MA).  Sendai virus (SV, Cantrell strain) was purchased 
from Charles River Laboratories (Wilmington, MA).  Lipofectamine 2000 was from 
Invitrogen (Carlsbad, CA).  Genejuice was from Novagen (Madison, WI).  ZVAD-FMK 
was from Calbiochem (San Diego, CA). AIM2, pro-IL-1β, ASC and caspase-1 were as 
described (16, 17). 
 
Mice 
C57BL/6 mice were from Jackson Laboratories (Bar Harbor, ME).  Caspase-1 
deficient mice were a gift from M. Starnbach (Harvard Medical School, MA).  ASC-, 
NLRP3- and NLRP12-deficient mice were generated by Millennium Pharmaceuticals 
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(Cambridge, MA) and were backcrossed 8-11 generations to C57BL/6 background.  
MyD88-, TLR2-, TLR9- and TLR2/9-deficient mice were a gift from S. Akira (Nippon 
Medical School, Japan).  All experiments were conducted with mice maintained under 
specific pathogen-free conditions in the animal facilities at the UMASS Medical School 
and were carried out in accordance with the guidelines set forth by the Institutional 
Animal Care and Use Committee. 
 
Cell Culture, Stimulation and ELISA 
HEK293T cells (5 x 104 cells/well) in 96-well plates were co-transfected in 
triplicate using GeneJuice (4 µl/ml) with plasmids encoding pro-IL-1β and the indicated 
expression plasmids (total DNA, 200 ng).  Cultures were incubated for two hours then 
exposed to sup ODN (3 µM) or left untreated; 24hrs later supernatants were collected and 
cells were lysed using a 1% NP-40 lysis buffer.  PEC, BMDM and BMDC were 
generated as described (17, 222).  Peritoneal exudate neutrophils were harvested 4 hrs 
after i.p. injection of 1 ml of thioglycolate, as described (117).  Cells were plated at 2x105 
per well for ELISA, 2-5x106 per well for immunoblotting.  Cells were treated with LPS 
(200 ng/ml) for 2 hrs prior to the addition sup ODN or CpG ODN then incubated for an 
additional hour before secondary stimulation.  ATP (5 mM) or Nigericin (10 µM) were 
added one hour before harvesting supernantants and lysates.  P oly(dA:dT) was 
transfected using Lipofectamine 2000 a t a concentration of 0.5 µg/ml, 6 hrs before 
harvesting.  Cells were infected with MCMV and HSV-1 at an MOI of 10.  Cells were 
exposed to Sendai virus at 200 HAU/ml.  Cells were challenged with L. monocytogenes 
at an MOI of 5 for 1 hr.  Cells were then washed twice and media containing gentamicin 
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(100 µg/ml) was added.  A ll infections were incubated for 16 hrs before harvest. 
Supernatants from cell culture experiments were assayed for IL-1β (BD Biosciences, 
Franklin Lakes, NJ) and IL-18 (R&D Systems Piscataway, NJ) by sandwich ELISA. 
 
Nanostring and RT-QPCR experiments 
Cells were treated as described above and RNA was purified using an RNeasy Mini Kit 
(QIAGEN).  T otal RNA was hybridized to a custom gene expression CodeSet and 
analyzed on a n nCounter Digital Analyzer.  Counts were normalized to internal and 
endogenous controls per Nanostring Technologies’ specifications.  A  pseudocount was 
ascribed to all values such that the smallest value in the dataset was equal to 1.  Values 
were log-transformed and displayed via heat map (Euclidean clustering) generated using 
the ggplot package within the open source R software environment.  c DNA was 
synthesized from total RNA and quantitative RT-PCR analysis was performed as 
previously described (223).   G ene expression is shown as a ratio of gene copy number 
per 100 copies of β-Actin + SD. 
 
Western Blotting 
Supernatants were harvested and precipitated by methanol chloroform extraction.  
Cells were washed twice with PBS and lysed using a 1% NP-40 buffer.  Immunoblotting 
was performed as described (16).  Anti-Flag antibody (M2) was from Sigma, anti-murine 
caspase-1 p10 (sc-514) from Santa Cruz Biotechnology Inc. (Santa Cruz, CA), anti-
murine caspase-1 p20 (5B10) from eBioscience, anti-murine IL-1β from R&D Systems 
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(Minneapolis, MN), and anti-mouse HMGB1 (3E8) was from BioLegend (San Diego, 
CA).    
 
ASC Oligomerization Assay 
 ASC oligomerization assay was performed as described with minor modifications 
(101). In brief, BMDM (1 x 107 cells/condition) were primed with LPS (200 ng/ml) for 2 
hrs prior to the addition of A151 or C151 (3 µM).  After 30 minutes, 25 µM of zVAD-
FMK was added followed 30 minutes later by poly(dA:dT) transfection (0.5 µg/ml) using 
Lipofectamine 2000.  Cells were washed and lysed with 1% NP-40 lysis buffer 3 hrs after 
poly(dA:dT) challenge.  Lysates were cleared by centrifugation at 300 g.  
Macromolecular structures were then pelleted by centrifugation at 4,500 x g, resuspended 
in 50 µl CHAPS buffer, and cross-linked with disuccinimidyl suberate (2 µM) (Pierce 
Thermo Scientific, Rockford, IL).  Supernatants from this step were saved and labeled 
‘lysate’ in ASC blots.  The pellet was washed, resuspended in Laemmli buffer, incubated 
overnight with shaking at 4 oC, then boiled and electrophoresed on a 12% SDS-
acrylamide gel as the ‘cross-linked’ fraction.  Blots were probed with anti-ASC antibody 
(N-15-R, Santa Cruz Biotechnology).      
 
Confocal Microscopy 
Confocal microscopy was performed using a Leica SP2 AOBS confocal laser 
scanning microscope.  Immortalized murine macrophages stably expressing AIM2- or 
ASC-citrine constructs were plated at 2 x  106 cells/ml on glass bottom 35 mM culture 
dishes (MatTek corportation, Ashland, MA) and allowed to adhere.  A151 or C151 was 
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added one hour prior to transfection with poly(dA:dT) or exposure to nigericin.  T wo 
hours after poly(dA:dT) challenge or 30 minutes after nigericin exposure cultures were 
photographed.  The total number of fluorescent cells was recorded in more than twenty 
independent fields representing more than 1000 cells and divided into those displaying 
diffuse cytoplasmic staining and those exhibiting speck formation.  Little variability in 
the percent of cell exhibiting speck formation was observed between experiments.  
Graphs quantifying speck formation were calculated by combining data from three 
independent experiments.   
 
Pull-down Assay  
Immortalized murine macrophages (5 x 106 cells/condition) were lysed in an ice-
cold high salt lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris HCl, pH 7.9, 100 mM 
EDTA, 10% glycerol, 10 mM NaF, dithiothreitol (DTT) and protease inhibitor cocktail as 
described previously (224).  Cell debris was removed by centrifugation and total lysate 
was incubated with 6 µg of 3’-biotinylated A151 and pre-washed streptavidin-agarose 
beads (50% w/v) for 2 hrs at 4 oC. For competition assays, an increasing amount of 
poly(dA:dT) was mixed with biotinylated A151 before addition to the lysate.  Bead 
pellets were washed, boiled in Laemmli buffer, and electrophoresed on a 12% SDS-
polyacrylamide gel.  Blots were probed with polyclonal anti-mouse AIM2 antibody from 
Genentech (4G9, San Francisco, CA) and anti-mouse β-actin (AC-74, Sigma).       
 
Statistical Analysis  
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One-way analysis of variance followed by the Bonferroni post-test was performed 
using Prism 4 Software (GraphPad, San Diego, CA).  P values of <0.05 were considered 
significant.   
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Chapter V Discussion and Perspectives 
 
 
Cells of the innate and adaptive immune systems utilize a v ariety of PRRs to 
recognize DNA.  Endosomal nucleic acid receptors such as TLR7, TLR8, and TLR9 are 
crucial for host defense, yet can have deleterious functions in immune-mediated diseases.  
TLR9 responds to ssDNA containing unmethylated CpG motifs (225).  In humans TLR9 
expression is limited to plamacytoid dendritic cells and B cells while it i s more widely 
expressed in mice.  As our understanding of TLR9 has expanded, harnessing TLR-driven 
cellular responses to modulate inflammation and immunity has become reality.  S hort 
synthetic oligodeoxynucleotides (ODN) containing CpG motifs have remarkable 
immunostimulatory properties such as driving cytokine and IFN production, enhancing 
APC functional, and lymphocyte maturation (8).  T hese CpG ODNs have tantalizing 
immunotherapeutic potential.  By virtue of their stimulatory properties they can be used 
to enhance vaccine responses, as anti-cancer agents, and to reduce the transmission of 
HIV (193, 226, 227) .  Interestingly, these CpG ODN have been reported to suppress 
pathological immunity as evidenced by their beneficial effects on allergic diseases such 
as asthma, and autoimmune diseases such as diabetes (228-230).  How CpG treatment 
can reduce certain inflammatory disease and exacerbate others is still poorly understood 
(231).  It has been suggested that these seemingly paradoxical effects are due to TLR9-
dependent induction of the immunosuppressive enzyme IDO and the stimulation of 
regulatory T cell responses however their mechanisms of action may be more complex 
than previously thought (230, 232).  
In concert with the establishment of synthetic stimulatory CpG ODNs, a number 
of groups have developed suppressive ODN (sup ODN) sequences that compete with 
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CpG motifs thereby blocking TLR9 activation.  D r. Klinman and collaborators have 
pioneered the use of the telomere-derived suppressive A151 construct (149).  O ther 
groups have transformed CpG ODNs into suppressive constructs by altering their 
sequence, for example by replacing the cytosine residue with a guanine (GpG) or 
reversing the two residues (GpC) (150, 160).  That these constructs were first recognized 
for their ability to prevent TLR9 activation has led many to explain their in vivo effects in 
this context.  However more recent studies show the potency of inhibition by sup ODNs 
is strongly affected by sequence - a phenomenon not explained by their relative avidity to 
the TLR9 ectodomain (148).  In addition suppression of Th1 differentiation is observed 
even in TLR9-deficient CD4+ T cells suggesting that their biological activity may have 
more complex mechanisms of action than simply blocking TLR9 (154).  Indeed, recent 
evidence suggests certain GpC motifs can activate TLR7, the well-studied 2114 construct 
may prevent TLR2 activation and A151 can bind directly to STAT1 and STAT4 thereby 
interfering with Type I IFN and cytokine signaling (153, 158, 160 ).  Despite our 
incomplete understanding of their mechanisms of action, the anti-inflammatory range and 
therapeutic value of sup ODNs is promising. Administration of A151 has been shown to 
be beneficial in murine models of CpG and collagen-induced arthritis, toxic shock, 
systemic lupus erythematosus, atherosclerosis, silica-induced pulmonary inflammation 
and influenza infection (149-156).  Likewise GpG has been used to suppress 
experimental autoimmune encephalomyelitis and lupus nephritis (150, 233).  
In recent years, a number of cytosolic DNA sensors have been discovered 
including IFI16, AIM2, DDX41 and cGAS (16, 49, 68, 70).  In the second chapter of this 
dissertation we explored the role of suppressive oligodeoxynucleotides in inhibiting 
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cytosolic DNA sensing pathways.  Using the synthetic dsDNA ligand poly(dA:dT) and 
pathogens including HSV-1, MCMV and Listeria monocytogenes we found suppressive 
ODNs were able to block dsDNA-specific cytosolic receptors while having no effect on 
TLR4, RIG-I or NLRP3 mediated signaling.  Moreover backbone chemistry was found to 
be of central importance to inhibition as only phosphorothioate (PS) DNA was able to 
bind to receptors and suppress Type I IFN and cytokine production.  Interestingly while 
the guanine-rich A151 construct more potently inhibited AIM2 signaling, the C151 
construct was a more potent inhibitor of type I IFN and ISG.  In support of an affinity-
based model of competitive inhibition, the potency of these constructs correlated with 
their relative affinity for the AIM2 and IFI16 receptors.  Using a number of different 
constructs we noticed that while total guanine or adenine content affected inhibitory 
potency the specific sequence did not appear to be of great importance.  For example, 
class B stimulatory ODNs 1826 and 10104 inhibited AIM2 with a similar potency to 
A151.  T his off target mechanism of action may contribute to many of the anti-
inflammatory effects of suppressive and stimulatory ODN alike.   
Evidence that PS backbone ssDNA constructs, even those containing stimulatory 
CpG motifs, can mediate inhibition of cytosolic receptor signaling has not been 
previously reported and is an important concept.  Particularly in light of the numerous 
clinical trials in all phases of development using CpG ODN c onstructs (234).  With 
widespread use as vaccine adjuvants it is possible CpG ODN-mediated suppression of 
cytosolic sensing pathways may enhance susceptibility to certain pathogenic infections.  
This was evinced in a study by Trieu et al. which demonstrated that treatment with the 
suppressive 2114 construct increased bacterial loads of the intracellular pathogen 
 113 
Salmonella typhimurium by suppressing NF-κB-dependent cytokine responses in a 
TLR9-independent manner (158).  In addition to CpG ODN, antisense PS constructs are 
widely employed in the laboratory to silence expression of target proteins and have 
recently found traction as therapies in the clinic.  F ormivirsen - a 21bp PS antisense 
construct - has already been approved by the FDA for the treatment of cytomegalovirus 
retinitis in immunocompromised patients (235).  However numerous studies report 
unexplained, non-sequence specific effects of antisense constructs (236, 237).  For 
example, treatment of human leukemia HL-60 cells with PS but not PD antisense 
constructs has also been reported to inhibit proliferation and induce cell death in a 
manner that is independent of sequence (131).  It is tempting to speculate that interactions 
between these constructs and members of the PYHIN family, such as IFI16 and p204, 
known to regulate cell cycle progression and survival, may underlie many of these 
previously unexplained biological effects (80). 
In addition to describing the role of backbone chemistry in ODN potency and 
affinity for PRRs, this thesis has begun to define the contributions of nucleotide content 
to inhibition.  Our findings indicate that by altering sequences and refining the dose of 
these constructs it ma y be possible to selectively block specific pathways allowing 
examination of the relative contributions of different cytosolic receptors to the 
inflammatory response.  Alternatively, antisense sequences or dosing strategies could be 
chosen to minimize off target effects.  However, more work, defining the dissociation 
constants of these sup ODN, is needed to further explore the contributions of sequence to 
inhibitory potency.  F inally, we have preliminary evidence that indicates suppressive 
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ODN can interfere with signaling mediated by other cytoplasmic receptors such as 
DDX41 and cGAS suggesting additional anti-inflammatory mechanisms exist.   
The cytokines IL-1β and IL-18 play a crucial role in the immune response to 
HSV-1.  Mice lacking IL-1β or IL-18 are unable to control viral dissemination and are 
susceptible to lethal encephalitis (177, 201).  In the third chapter of this dissertation the 
innate pathways responsible for both inducing the pro-forms and ultimately maturing 
these cytokines were investigated.  The TLR2-MyD88 signal axis was found to be 
essential for induction of pro-IL-1β in macrophages and CDCs.  Induction of pro-IL-1β 
was blocked by the viral ICP0, a protein that has been shown to induce degradation of 
MyD88 (168).  In contrast, optimal pro-IL-18 induction required both MyD88 and 
STING suggesting both TLR and cytosolic receptor pathways synergistically control 
expression of this cytokine.  Consistent with the need to both ‘prime’ and ‘license’ the 
inflammasome, infection with HSV-1 also stimulated MyD88-dependent expression of 
NLRP3 in dendritic cells.  Where other attempts to detect IL-1β production have failed, 
our LPS prime, HSV-1 challenge strategy results in secretion of mature IL-1β (181, 212).  
In macrophages and DCs secretion of IL-1β was dependent on NLRP3.  Although we did 
not identify a specific ligand for NLRP3, inactivation of HSV-1 by UV-irradiation 
prevented IL-1β production indicating replication competent virus is required for 
activation.  In spite of priming with LPS to produce high levels of pro-IL-1β, treatment 
with the wild-type KOS strain of HSV-1 induced lower amounts of IL-1β secretion than 
the ICP0-deficient 7134 strain.  It is possible that ICP0 also plays a direct role in blocking 
inflammasome signaling through the degradation of inflammasome components as has 
been reported for IFI16 (181).  Alternatively, it may indirectly influence cytokine 
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production by inhibiting Type I IFN signaling, which is known to signal in a paracrine 
and autocrine manner to induce ISGs and amplify cytokine secretion (238).  Additional 
studies beyond the scope of this dissertation are required to further investigate the 
functional interaction between the viral protein ICP0 and NLRP3 signaling.   
This study also reveals a role for NLRP12 in inflammasome signaling in 
neutrophils, another cell type that plays a critical role in the acute immune response 
against HSV-1.  N eutrophils rapidly infiltrate sites of HSV-1 infection and have been 
shown adhere to infected cells and phagocytose antibody coated herpes virions (239-
241).  Depletion of neutrophils in the bloodstream before corneal infection with HSV-1 
caused increased viral replication and dissemination rendering mice significantly more 
susceptible to lethal encephalitis (242).  Inflammasome signaling and IL-1β production 
have been shown to be important for neutrophil recruitment and neutrophil extracellular 
trap (NET) formation in cases of bacterial infection and sterile inflammation (243-245).  
Although other serine proteases have been implicated in IL-1β processing (89), we 
demonstrate here that IL-1β secretion in neutrophils responding to HSV-1 is largely 
dependent on the NLRP12 and ASC.   
Inhibition of IL-1β signaling is a potential therapeutic strategy in a variety of 
inflammatory disorders including coronary artery disease and inflammatory arthritis and 
is beneficial in some manifestations of HSV-1 infection (215, 246).  Anakinra, a 
recombinant IL-1 receptor antagonist is used in the treatment of rheumatoid arthritis but 
can lead to pain at the injection site and increased risk of infection (247).  As 
demonstrated, different innate cell types rely on different receptors to assemble 
inflammasomes in response to HSV-1.  T hus, rather than general inhibition of IL-1β 
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signaling, targeted therapy directed against specific receptors may reduce excessive 
immune responses without impairing the ability to fight infection.  For this reason a more 
comprehensive understanding of the cell type specific mechanisms responsible for IL-1β 
and IL-18 production is essential for the development of novel and balanced therapeutic 
interventions.   
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